WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS Fluoroquinolones, including levofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together [see Warnings and Precautions (5.1)], including: Tendinitis and tendon rupture [see Warnings and Precautions (5.2)] Peripheral neuropathy [see Warnings and Precautions (5.3)] Central nervous system effects [see Warnings and Precautions (5.4)] Discontinue levofloxacin immediately and avoid the use of fluoroquinolones, including levofloxacin, in patients who experience any of these serious adverse reactions [see Warnings and Precautions (5.1)] Fluoroquinolones, including levofloxacin, may exacerbate muscle weakness in patients with myasthenia gravis. Avoid levofloxacin in patients with a known history of myasthenia gravis [see Warnings and Precautions (5.5)].
Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1 to 5.15)], reserve levofloxacin for use in patients who have no alternative treatment options for the following indications: Uncomplicated urinary tract infection [see Indications and Usage (1.12)] Acute bacterial exacerbation of chronic bronchitis [see Indications and Usage (1.13)] Acute bacterial sinusitis [see Indications and Usage (1.14)]. WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS See full prescribing information for complete boxed warning.
Fluoroquinolones, including levofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together (5.1), including:
- Tendinitis and tendon rupture (5.2)
- Peripheral neuropathy (5.3)
- Central nervous system effects (5.4) Discontinue levofloxacin immediately and avoid the use of fluoroquinolones, including levofloxacin, in patients who experience any of these serious adverse reactions (5.1) Fluoroquinolones, including levofloxacin, may exacerbate muscle weakness in patients with myasthenia gravis. Avoid levofloxacin in patients with a known history of myasthenia gravis [see Warnings and Precautions (5.5)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions (5.1 to 5.15), reserve levofloxacin for use in patients who have no alternative treatment options for the following indications:
- Uncomplicated urinary tract infection (1.12)
- Acute bacterial exacerbation of chronic bronchitis (1.13)
- Acute bacterial sinusitis (1.14)
Use: Labeled indications
- Levofloxacin tablets are a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with infections caused by designated, susceptible bacteria and in pediatric patients where indicated ( 1 , 12.4 ).
- and Community Acquired ( 1.2, 1.3 ) Skin and Skin Structure Infections (SSSI): Complicated
- and Uncomplicated
- Chronic bacterial prostatitis
- Inhalational Anthrax, Post-Exposure in adult and pediatric patients
- Plague in adult and pediatric patients
- Urinary Tract Infections (UTI): Complicated ( 1.9 , 1.10 ) and Uncomplicated
- Acute Pyelonephritis
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Levofloxacin tablets are a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with infections caused by designated, susceptible bacteria and in pediatric patients where indicated (1, 12.4). Pneumonia: Nosocomial (1.1) and Community Acquired (1.2, 1.3) Skin and Skin Structure Infections (SSSI): Complicated (1.4) and Uncomplicated (1.5) Chronic bacterial prostatitis (1.6) Inhalational Anthrax, Post-Exposure in adult and pediatric patients (1.7) Plague in adult and pediatric patients (1.8) Urinary Tract Infections (UTI): Complicated (1.9, 1.10) and Uncomplicated (1.12) Acute Pyelonephritis (1.11) Acute Bacterial Exacerbation of Chronic Bronchitis (1.13) Acute Bacterial Sinusitis (1.14) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria (1.15). 1.1 Nosocomial Pneumonia Levofloxacin tablets are indicated in adult patients for the treatment of nosocomial pneumonia due to methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae.
Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7 to 14 day Treatment Regimen Levofloxacin tablets are indicated in adult patients for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)].
MDRSP isolates are isolates resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2 nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin tablets are indicated in adult patients for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)]. 1.4 Complicated Skin and Skin Structure Infections Levofloxacin tablets are indicated in adult patients for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin tablets are indicated in adult patients for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin tablets are indicated in adult patients for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin tablets are indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis in adults and pediatric patients, 6 months of age and older [see Dosage and Administration (2.2)]. The effectiveness of levofloxacin tablets is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit.
Levofloxacin tablets have not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin tablets in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin tablets therapy should only be used when the benefit outweighs the risk [see Clinical Studies (14.9)]. 1.8 Plague Levofloxacin tablets are indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older [see Dosage and Administration (2.2)].
Efficacy studies of levofloxacin tablets could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin tablets are indicated in adult patients for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin tablets are indicated in adult patients for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin tablets are indicated in adult patients for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin tablets are indicated in adult patients for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus.
Because fluoroquinolones, including levofloxacin tablets, have been associated with serious adverse reactions [see Warnings and Precautions (5.1 to 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin tablets for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin tablets are indicated in adult patients for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. Because fluoroquinolones, including levofloxacin tablets, have been associated with serious adverse reactions [see Warnings and Precautions (5.1 to 5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin tablets for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10 to 14 day Treatment Regimens Levofloxacin tablets are indicated in adult patients for the treatment of acute bacterial sinusitis (ABS) due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)].
Because fluoroquinolones, including levofloxacin tablets, have been associated with serious adverse reactions [see Warnings and Precautions (5.1 to 5.15)] and for some patients ABS is self-limiting, reserve levofloxacin tablets for treatment of ABS in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin tablets and other antibacterial drugs, levofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.
In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)].
Therapy with levofloxacin tablets may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin tablets. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance.
Contraindications
- Hypersensitivity to levofloxacin or other quinolones
Contraindications (US label) US FDA label
4 CONTRAINDICATIONS Levofloxacin tablets are contraindicated in persons with known hypersensitivity to levofloxacin, or other quinolone antibacterials [see Warnings and Precautions (5.3)]. Known hypersensitivity to levofloxacin tablets or other quinolones (4, 5.7)
Dosing: Adult
- Community-acquired pneumonia: 500 mg every 24 hours for 7 to 14 days, or 750 mg every 24 hours for 5 days
- Nosocomial pneumonia; complicated skin infection: 750 mg every 24 hours for 7 to 14 days
- Chronic bacterial prostatitis: 500 mg every 24 hours for 28 days
- Administer levofloxacin tablets to pediatric patients weighing 30 kg and greater only (2.1, 2.2). Levofloxacin tablets cannot be administered to pediatric patients who weigh less than 30 kg because of the limitations of the available strengths. Alternative formulations of levofloxacin may be considered for pediatric patients who weigh less than 30 kg (2.2). Dosage in Adult and Pediatric Patients with Creatinine Clearance greater than or equal to 50 mL/minute (2.1. 2.2) Type of Infection Dose Every 24 hours Duration (days) Nosocomial Pneumonia (1.1)
- 750 mg 7 to 14 Community Acquired Pneumonia (1.2)
- 500 mg 7 to 14 Community Acquired Pneumonia (1.3)
- 750 mg 5 Complicated SSSI (1.4)
- 750 mg 7 to 14 Uncomplicated SSSI (1.5)
- 500 mg 7 to 10 Chronic Bacterial Prostatitis (1.6)
- 500 mg 28 Inhalational Anthrax (Post-Exposure) (1.7)
- Adults and Pediatric Patients 50 kg or greater Pediatric Patients 30 kg to less than 50 kg (2.2)
- 500 mg 250 mg every 12 hours 60 60 Plague (1.8)
- Adults and Pediatric Patients 50 kg or greater Pediatric Patients 30 kg to less than 50 kg (2.2)
- 500 mg 250 mg every 12 hours 10 to 14 10 to 14 Complicated UTI (1.9)
- or Acute Pyelonephritis (1.11)
- 750 mg 5 Complicated UTI (1.10)
- or Acute Pyelonephritis (1.11)
- 250 mg 10 Uncomplicated UTI (1.12)
- 250 mg 3 Acute Bacterial Exacerbation of Chronic Bronchitis (1.13)
- 500 mg 7 Acute Bacterial Sinusitis (1.14)
- 750 …
2.1 Dosage of Levofloxacin Tablets in Adult Patients with Creatinine Clearance
2.1 Dosage of Levofloxacin Tablets in Adult Patients with Creatinine Clearance ≥ 50 mL/minute The usual dose of levofloxacin tablets is 250 mg, 500 mg, or 750 mg administered orally every 24 hours, as indicated by infection and described in Table 1. These recommendations apply to patients with creatinine clearance ≥ 50 mL/minute.
For patients with creatinine clearance less than 50 mL/min, adjustments to the dosing regimen are required [see Dosage and Administration (2.3)]. Table 1: Dosage of Levofloxacin Tablets in Adult Patients with Creatinine Clearance greater than or equal to 50 mL/minute) Type of Infection * Dosed Every 24 hours Duration (days) † Nosocomial Pneumonia 750 mg 7 to 14 Community Acquired Pneumonia ‡ 500 mg ‡ 7 to 14 ‡ Community Acquired Pneumonia § 750 mg § 5 § Complicated Skin and Skin Structure Infections (SSSI) 750 mg 7 to 14 Uncomplicated SSSI 500 mg 7 to 10 Chronic Bacterial Prostatitis 500 mg 28 Inhalational Anthrax (Post-Exposure), adult and pediatric patients weighing 50 kg Þ,ß or greater Pediatric patients weighing 30 kg to less than 50 kg Þ,ß 500 mg see Table 2 below (2.2) 60 ß 60 ß Plague, adult and pediatric patients weighing 50 kg à or greater Pediatric patients weighing 30 kg to less than 50 kg 500 mg see Table 2 below (2.2) 10 to 14 10 to 14 Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) ¶ 750 mg 5 Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) # 250 mg # 10 # Uncomplicated Urinary Tract Infection 250 mg 3 Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) 500 mg 7 Acute Bacterial Sinusitis (ABS) 750 mg 5 500 mg 10 to 14 * Due to the designated pathogens [see Indications and Usage (1)]. † Sequential therapy (intravenous levofloxacin to oral levofloxacin tablets) may be instituted at the discretion of the healthcare provider. ‡ Due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Indications and Usage (1.2)]. § Due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Indications and Usage (1.3)]. ¶ This regimen is indicated for cUTI due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and AP due to E. coli, including cases with concurrent bacteremia. # This regimen is indicated for cUTI due to Enterococcus faecalis, Enterococcus cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa; and for AP due to E. coli. Þ Drug administration should begin as soon as possible after suspected or confirmed exposure to aerosolized B. anthracis.
This indication is based on a surrogate endpoint. Levofloxacin plasma concentrations achieved in humans are reasonably likely to predict clinical benefit [see Clinical Studies (14.9)]. ß The safety of levofloxacin tablets in adults for durations of therapy beyond 28 days or in pediatric patients for durations beyond 14 days has not been studied.
An increased incidence of musculoskeletal adverse events compared to controls has been observed in pediatric patients [see Warnings and Precautions (5.12), Use in Specific Populations (8.4), and Clinical Studies (14.9)]. Prolonged levofloxacin tablets therapy should only be used when the benefit outweighs the risk. à Drug administration should begin as soon as possible after suspected or confirmed exposure to Yersinia pestis.
Higher doses of levofloxacin tablets typically used for treatment of pneumonia can be used for treatment of plague, if clinically indicated.
2.2 Dosage of Levofloxacin Tablets in Pediatric Patients with Inhalational Anthrax or Plague
2.2 Dosage of Levofloxacin Tablets in Pediatric Patients with Inhalational Anthrax or Plague The dosage of levofloxacin tablets for inhalational anthrax (post-exposure) and plague in pediatric patients who weigh 30 kg or greater is described below in Table 2. Levofloxacin tablets cannot be administered to patients who weigh less than 30 kg because of the limitations of the available strength.
Alternative formulations of levofloxacin may be considered for pediatric patients who weigh less than 30 kg. Table 2: Levofloxacin Tablets Dosage in Pediatric Patients Weighing 30 kg or greater with Inhalational Anthrax (Post-Exposure) and Plague* Type of Infection * Dose Frequency Duration † Inhalational Anthrax (post-exposure) ‡,§ Pediatric patients weighing 50 kg or greater 500 mg every 24 hours 60 days § Pediatric patients weighing 30 kg to less than 50 kg 250 mg every 12 hours 60 days § Plague ¶ Pediatric patients weighing 50 kg or greater 500 mg every 24 hours 10 to 14 days Pediatric patients weighing 30 kg to less than 50 kg 250 mg every 12 hours 10 to 14 days * Due to Bacillus anthracis [see Indications and Usage (1.13)] and Yersinia pestis [see Indications and Usage (1.14)]. † Sequential therapy (intravenous levofloxacin injection to oral levofloxacin tablets) may be instituted at the discretion of the healthcare provider. ‡ Begin levofloxacin tablets as soon as possible after suspected or confirmed exposure to aerosolized B. anthracis. § The safety of levofloxacin tablets in pediatric patients for durations of therapy beyond 14 days has not been studied. [see Warnings and Precautions (5.12), Use in Specific Populations (8.4), and Clinical Studies (14.9)].
Begin levofloxacin tablets as soon as possible after suspected or confirmed exposure to Yersinia pestis.
2.3 Dosage Adjustment in Adults with Renal Impairment
2.3 Dosage Adjustment in Adults with Renal Impairment Administer levofloxacin tablets with caution in patients with renal impairment. Careful clinical observation and appropriate laboratory studies should be performed prior to and during therapy since elimination of levofloxacin may be reduced in these patients. In patients with renal impairment (creatinine clearance less than 50 mL/min), adjustment of the dosage regimen is necessary to avoid the accumulation of levofloxacin due to decreased clearance [see Use in Specific Populations (8.6)].
No adjustment is necessary for patients with a creatinine clearance greater than or equal to 50 mL/minute. Table 3 shows how to adjust dose based on creatinine clearance. Table 3: Dosage Adjustment in Adult Patients with Renal Impairment (Creatinine Clearance less than 50 mL/minute) Creatinine Clearance greater than or equal to 50 mL/minute Creatinine Clearance 20 to 49 mL/minute Creatinine Clearance 10 to 19 mL/minute Hemodialysis or Chronic Ambulatory Peritoneal Dialysis (CAPD) 750 mg every 24 hours 750 mg every 48 hours 750 mg initial dose, then 500 mg every 48 hours 750 mg initial dose, then 500 mg every 48 hours 500 mg every 24 hours 500 mg initial dose, then 250 mg every 24 hours 500 mg initial dose, then 250 mg every 48 hours 500 mg initial dose, then 250 mg every 48 hours 250 mg every 24 hours No dosage adjustment required 250 mg every 48 hours.
If treating uncomplicated UTI, then no dosage adjustment is required No information on dosing adjustment is available
2.4 Drug Interaction With Chelation Agents
2.4 Drug Interaction With Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins Levofloxacin tablets should be administered at least two hours before or two hours after antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc or didanosine chewable/buffered tablets or the pediatric powder for oral solution [see Drug Interactions (7.1) and Patient Counseling Information (17)].
2.5 Important Administration Instructions
2.5 Important Administration Instructions Levofloxacin tablets can be administered without regard to food. If patients miss a dose, they should take it as soon as possible anytime up to 8 hours prior to their next scheduled dose. If less than 8 hours remain before the next dose, wait until their next scheduled dose.
2.6 Hydration for Patients Receiving
2.6 Hydration for Patients Receiving Levofloxacin Tablets Adequate hydration of patients receiving levofloxacin tablets should be maintained to prevent the formation of highly concentrated urine. Crystalluria and cylindruria have been reported with quinolones [see Adverse Reactions (6) and Patient Counseling Information (17)].
Dosing: Altered kidney function
Levofloxacin clearance falls and its half-life lengthens when creatinine clearance (CrCl) drops below 50 mL/min, so the US label extends the dosing interval. Neither hemodialysis nor continuous ambulatory peritoneal dialysis (CAPD) removes it, so no supplemental doses are needed.
Kidney function measure: Label uses creatinine clearance (CrCl, mL/min).
Show full dosing details
- CrCl ≥60 mL/min
- Usual dose: 250, 500 or 750 mg every 24 hours by infection (label).
- CrCl 30–59 mL/min
- CrCl ≥50: usual dose. CrCl 20–49: 750 mg every 48 hours; or 500 mg once, then 250 mg every 24 hours; 250 mg regimen unchanged (label).
- CrCl 15–29 mL/min
- CrCl 20–49: as above. CrCl 10–19: 750 mg once, then 500 mg every 48 hours; or 500 mg once, then 250 mg every 48 hours; 250 mg regimen becomes every 48 hours (no change for uncomplicated UTI) (label).
- CrCl <15 mL/min (not on dialysis)
- CrCl 10–19: as above. Below 10 not on dialysis: not addressed in label; specialist input.
- Hemodialysis (intermittent)
- 750 mg once, then 500 mg every 48 hours; or 500 mg once, then 250 mg every 48 hours. No supplemental dose after dialysis. 250 mg regimen: no information (label).
- Peritoneal dialysis
- CAPD: same as hemodialysis; no supplemental dose (label). For PD-associated peritonitis (ISPD 2022, systemic): oral 250 mg daily or 500 mg every 48 hours (Table 6).
- CRRT
- Not in label. Limited data: about 250 mg every 24 hours at low effluent; poor target attainment on CVVHD, so avoid as gram-negative monotherapy; specialist input (Li 2020).
- Dialyzable? No: not efficiently removed by hemodialysis or peritoneal dialysis (label).
- Monitoring Tendon rupture, QT prolongation, dysglycemia, central nervous system effects; risk higher in older adults and kidney impairment.
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Normal kidney function: usual pediatric dosing (label).
- eGFR 30–59
- No pediatric kidney-dosing data in the US label; specialist (pediatric nephrology) input.
- eGFR 15–29
- No pediatric kidney-dosing data in the US label; specialist (pediatric nephrology) input.
- eGFR <15 (not on dialysis)
- No pediatric kidney-dosing data in the US label; specialist (pediatric nephrology) input.
- Hemodialysis (intermittent)
- No pediatric data.
- Peritoneal dialysis
- No pediatric data.
- CRRT
- No pediatric data.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Renal impairment US FDA label
2.1 Dosage of Levofloxacin Tablets in Adult Patients with Creatinine Clearance ≥ 50 mL/minute The usual dose of levofloxacin tablets is 250 mg, 500 mg, or 750 mg administered orally every 24 hours, as indicated by infection and described in Table 1. These recommendations apply to patients with creatinine clearance ≥ 50 mL/minute.
For patients with creatinine clearance less than 50 mL/min, adjustments to the dosing regimen are required [see Dosage and Administration (2.3)]. Table 1: Dosage of Levofloxacin Tablets in Adult Patients with Creatinine Clearance greater than or equal to 50 mL/minute) Type of Infection * Dosed Every 24 hours Duration (days) † Nosocomial Pneumonia 750 mg 7 to 14 Community Acquired Pneumonia ‡ 500 mg ‡ 7 to 14 ‡ Community Acquired Pneumonia § 750 mg § 5 § Complicated Skin and Skin Structure Infections (SSSI) 750 mg 7 to 14 Uncomplicated SSSI 500 mg 7 to 10 Chronic Bacterial Prostatitis 500 mg 28 Inhalational Anthrax (Post-Exposure), adult and pediatric patients weighing 50 kg Þ,ß or greater Pediatric patients weighing 30 kg to less than 50 kg Þ,ß 500 mg see Table 2 below (2.2) 60 ß 60 ß Plague, adult and pediatric patients weighing 50 kg à or greater Pediatric patients weighing 30 kg to less than 50 kg 500 mg see Table 2 below (2.2) 10 to 14 10 to 14 Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) ¶ 750 mg 5 Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) # 250 mg # 10 # Uncomplicated Urinary Tract Infection 250 mg 3 Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) 500 mg 7 Acute Bacterial Sinusitis (ABS) 750 mg 5 500 mg 10 to 14 * Due to the designated pathogens [see Indications and Usage (1)]. † Sequential therapy (intravenous levofloxacin to oral levofloxacin tablets) may be instituted at the discretion of the healthcare provider. ‡ Due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Indications and Usage (1.2)]. § Due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Indications and Usage (1.3)]. ¶ This regimen is indicated for cUTI due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and AP due to E. coli, including cases with concurrent bacteremia. # This regimen is indicated for cUTI due to Enterococcus faecalis, Enterococcus cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa; and for AP due to E. coli. Þ Drug administration should begin as soon as possible after suspected or confirmed exposure to aerosolized B. anthracis.
This indication is based on a surrogate endpoint. Levofloxacin plasma concentrations achieved in humans are reasonably likely to predict clinical benefit [see Clinical Studies (14.9)]. ß The safety of levofloxacin tablets in adults for durations of therapy beyond 28 days or in pediatric patients for durations beyond 14 days has not been studied.
An increased incidence of musculoskeletal adverse events compared to controls has been observed in pediatric patients [see Warnings and Precautions (5.12), Use in Specific Populations (8.4), and Clinical Studies (14.9)]. Prolonged levofloxacin tablets therapy should only be used when the benefit outweighs the risk. à Drug administration should begin as soon as possible after suspected or confirmed exposure to Yersinia pestis.
Higher doses of levofloxacin tablets typically used for treatment of pneumonia can be used for treatment of plague, if clinically indicated.
2.3 Dosage Adjustment in Adults with Renal Impairment Administer levofloxacin tablets with caution in patients with renal impairment. Careful clinical observation and appropriate laboratory studies should be performed prior to and during therapy since elimination of levofloxacin may be reduced in these patients. In patients with renal impairment (creatinine clearance less than 50 mL/min), adjustment of the dosage regimen is necessary to avoid the accumulation of levofloxacin due to decreased clearance [see Use in Specific Populations (8.6)].
No adjustment is necessary for patients with a creatinine clearance greater than or equal to 50 mL/minute. Table 3 shows how to adjust dose based on creatinine clearance. Table 3: Dosage Adjustment in Adult Patients with Renal Impairment (Creatinine Clearance less than 50 mL/minute) Creatinine Clearance greater than or equal to 50 mL/minute Creatinine Clearance 20 to 49 mL/minute Creatinine Clearance 10 to 19 mL/minute Hemodialysis or Chronic Ambulatory Peritoneal Dialysis (CAPD) 750 mg every 24 hours 750 mg every 48 hours 750 mg initial dose, then 500 mg every 48 hours 750 mg initial dose, then 500 mg every 48 hours 500 mg every 24 hours 500 mg initial dose, then 250 mg every 24 hours 500 mg initial dose, then 250 mg every 48 hours 500 mg initial dose, then 250 mg every 48 hours 250 mg every 24 hours No dosage adjustment required 250 mg every 48 hours.
If treating uncomplicated UTI, then no dosage adjustment is required No information on dosing adjustment is available
8.6 Renal Impairment Clearance of levofloxacin is substantially reduced and plasma elimination half-life is substantially prolonged in patients with renal impairment (creatinine clearance < 50 mL/min), requiring dosage adjustment in such patients to avoid accumulation. Neither hemodialysis nor continuous ambulatory peritoneal dialysis (CAPD) is effective in removal of levofloxacin from the body, indicating that supplemental doses of levofloxacin are not required following hemodialysis or CAPD [see Dosage and Administration (2.3)].
Patients with Renal Impairment Clearance of levofloxacin is substantially reduced and plasma elimination half-life is substantially prolonged in adult patients with impaired renal function (creatinine clearance < 50 mL/min), requiring dosage adjustment in such patients to avoid accumulation. Neither hemodialysis nor continuous ambulatory peritoneal dialysis (CAPD) is effective in removal of levofloxacin from the body, indicating that supplemental doses of levofloxacin are not required following hemodialysis or CAPD [see Dosage and Administration (2.3) and Use in Specific Populations (8.6)].
Dosing: Hepatic impairment
8.7 Hepatic Impairment Pharmacokinetic studies in patients with hepatic impairment have not been conducted. Due to the limited extent of levofloxacin metabolism, the pharmacokinetics of levofloxacin are not expected to be affected by hepatic impairment.
US FDA labelDosing: Pediatric
- Approved ages
- Inhalational anthrax (post-exposure) and plague: 6 months and older. Not established under 6 months; safety beyond 14 days not studied (label).
- Usual dose
- Tablet label: 50 kg or more, 500 mg every 24 hours; 30 kg to <50 kg, 250 mg every 12 hours. This tablet label gives no mg/kg dose for children under 30 kg.
- Maximum dose
- 500 mg/day for these indications (label).
- Neonates
- Neonates: not established (under 6 months).
Quinolones cause arthropathy in juvenile animals (label).
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
8.4 Pediatric Use Quinolones, including levofloxacin, cause arthropathy and osteochondrosis in juvenile animals of several species. [see Warnings and Precautions (5.12) and Animal Toxicology and/or Pharmacology (13.2)]. Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated in pediatric patients 6 months of age and older, for inhalational anthrax (post-exposure).
The risk-benefit assessment indicates that administration of levofloxacin to pediatric patients is appropriate. The safety of levofloxacin in pediatric patients treated for more than 14 days has not been studied [see Indications and Usage (1.7), Dosage and Administration (2.2) and Clinical Studies (14.9)]. Plague Levofloxacin is indicated in pediatric patients, 6 months of age and older, for treatment of plague, including pneumonic and septicemic plague due to Yersinia pestis (Y. pestis) and prophylaxis for plague.
Efficacy studies of levofloxacin could not be conducted in humans with pneumonic plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals. The risk-benefit assessment indicates that administration of levofloxacin to pediatric patients is appropriate [see Indications and Usage (1.8), Dosage and Administration (2.2) and Clinical Studies (14.10)].
Safety and effectiveness of levofloxacin tablets in pediatric patients below the age of six months have not been established. Pharmacokinetics following intravenous administration The pharmacokinetics of levofloxacin following a single intravenous dose were investigated in pediatric patients ranging in age from six months to 16 years.
Pediatric patients cleared levofloxacin faster than adult patients resulting in lower plasma exposures than adults for a given mg/kg dose [see Clinical Pharmacology (12.3) and Clinical Studies (14.9)]. Dosage in Pediatric Patients with Inhalational Anthrax or Plague For the recommended levofloxacin tablet dosage in pediatric patients with inhalational anthrax or plague, see Dosage and Administration (2.2).
Levofloxacin tablets cannot be administered to pediatric patients who weigh less than 30 kg because of the limitations of the available strengths. Alternative formulations of levofloxacin may be considered for pediatric patients who weigh less than 30 kg. Adverse Reactions In clinical trials, 1534 pediatric patients (6 months to 16 years of age) were treated with oral and intravenous levofloxacin.
Pediatric patients 6 months to 5 years of age received levofloxacin 10 mg/kg twice a day and pediatric patients greater than 5 years of age received 10 mg/kg once a day (maximum 500 mg per day) for approximately 10 days. Levofloxacin tablets can only be administered to pediatric patients with inhalational anthrax (post-exposure) or plague who are 30 kg or greater due to the limitations of the available strengths [see Dosage and Administration (2.2)].
A subset of pediatric patients in the clinical trials (1340 levofloxacin-treated and 893 non-fluoroquinolone-treated) enrolled in a prospective, long-term surveillance study to assess the incidence of protocol-defined musculoskeletal disorders (arthralgia, arthritis, tendinopathy, gait abnormality) during 60 days and 1 year following the first dose of the study drug. Pediatric patients treated with levofloxacin had a significantly higher incidence of musculoskeletal disorders when compared to the non-fluoroquinolone-treated children as illustrated in Table 7.
Levofloxacin tablets can only be administered to pediatric patients with inhalational anthrax (post-exposure) or plague who are 30 kg or greater due to the limitations of the available strengths [see Dosage and Administration (2.2)]. Table 7: Incidence of Musculoskeletal Disorders in Pediatric Clinical Trial Follow-up Period Levofloxacin N = 1340 Non-Fluoroquinolone * N = 893 p-value † 60 days 28 (2.1%) 8 (0.9%) p = 0.038 1 year ‡ 46 (3.4%) 16 (1.8%) p = 0.025 * Non-Fluoroquinolone: ceftriaxone, amoxicillin/clavulanate, clarithromycin † 2-sided Fisher’s Exact Test ‡ There were 1199 levofloxacin-treated and 804 non-fluoroquinolone-treated pediatric patients who had a one-year evaluation visit.
However, the incidence of musculoskeletal disorders was calculated using all reported events during the specified period for all pediatric patients enrolled regardless of whether they completed the 1-year evaluation visit. Arthralgia was the most frequently occurring musculoskeletal disorder in both treatment groups. Most of the musculoskeletal disorders in both groups involved multiple weight-bearing joints.
Disorders were moderate in 8/46 (17%) children and mild in 35/46 (76%) levofloxacin-treated pediatric patients and most were treated with analgesics. The median time to resolution was 7 days for levofloxacin-treated pediatric patients and 9 for non-fluoroquinolone-treated children (approximately 80% resolved within 2 months in both groups).
No pediatric patient had a severe or serious disorder and all musculoskeletal disorders resolved without sequelae. Vomiting and diarrhea were the most frequently reported adverse reactions, occurring in similar frequency in the levofloxacin-treated and non-fluoroquinolone-treated pediatric patients. In addition to the adverse reactions reported in pediatric patients in clinical trials, adverse reactions reported in adults during clinical trials or post-marketing experience [see Adverse Reactions (6)] may also be expected to occur in pediatric patients.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Geriatric patients are at increased risk for developing severe tendon disorders including tendon rupture when being treated with a fluoroquinolone such as levofloxacin. This risk is further increased in patients receiving concomitant corticosteroid therapy. Tendinitis or tendon rupture can involve the Achilles, hand, shoulder, or other tendon sites and can occur during or after completion of therapy; cases occurring up to several months after fluoroquinolone treatment have been reported.
Caution should be used when prescribing levofloxacin to elderly patients especially those on corticosteroids. Patients should be informed of this potential side effect and advised to discontinue levofloxacin and contact their healthcare provider if any symptoms of tendinitis or tendon rupture occur [see Boxed Warning; Warnings and Precautions (5.2); and Adverse Reactions (6.2)].
In Phase 3 clinical trials, 1,945 levofloxacin-treated patients (26%) were ≥ 65 years of age. Of these, 1,081 patients (14%) were between the ages of 65 and 74 and 864 patients (12%) were 75 years or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.
Severe, and sometimes fatal, cases of hepatotoxicity have been reported post-marketing in association with levofloxacin. The majority of fatal hepatotoxicity reports occurred in patients 65 years of age or older and most were not associated with hypersensitivity. Levofloxacin should be discontinued immediately if the patient develops signs and symptoms of hepatitis [see Warnings and Precautions (5.8)].
Epidemiologic studies report an increased rate of aortic aneurysm and dissection within two months following use of fluoroquinolones, particularly in elderly patients [see Warnings and Precautions (5.9)]. Elderly patients may be more susceptible to drug-associated effects on the QT interval. Therefore, precaution should be taken when using levofloxacin with concomitant drugs that can result in prolongation of the QT interval (e.g., Class IA or Class III antiarrhythmics) or in patients with risk factors for torsade de pointes (e.g., known QT prolongation, uncorrected hypokalemia) [see Warnings and Precautions (5.11)].
The pharmacokinetic properties of levofloxacin in younger adults and elderly adults do not differ significantly when creatinine clearance is taken into consideration. However, since the drug is known to be substantially excreted by the kidney, the risk of toxic reactions to this drug may be greater in patients with impaired renal function.
Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Clinical Pharmacology (12.3)].
Administration
2.5 Important Administration Instructions Levofloxacin tablets can be administered without regard to food. If patients miss a dose, they should take it as soon as possible anytime up to 8 hours prior to their next scheduled dose. If less than 8 hours remain before the next dose, wait until their next scheduled dose.
US FDA labelDosage forms
Philippines
- Film-coated tablet: 500 mg, 750 mg
- Solution for iv infusion: 5 mg/mL, 250 mg/50 mL, 500 mg/100 mL, 750 mg/150 mL
- ) solution for iv infusion: 5 mg/mL (500 mg/100 mL, 5 mg/mL (750 mg/15 mL, 5 mg/mL (750 mg/150 mL
- ) solution for intravenous infusion: 5 mg/mL (500 mg/100 mL, 5 mg/mL (750 mg/150 mL
- ) solution for i.v. infusion: 5 mg/mL (250 mg/50 mL, 5 mg/mL (500 mg/100 mL, 5 mg/mL (750 mg/150 mL, 5 mg/mL(500 mg/100 mL
- Solution for i.v. infusion: 5 mg/mL, 5 mg/mL (0.5 % w/v)/100 mL, 250 mg/50 mL, 500 mg/100 mL
- Ophthalmic solution: 5 mg/mL
- Tablet: 500 mg, 750 mg
- ) solution for infusion: 5 mg/mL (500 mg/100 mL
- Solution for infusion: 5 mg/mL, 500 mg/100 mL
and 7 more forms; see the products table.
Registered products in the Philippines
225 products registered with the Food and Drug Administration (FDA) Philippines list Levofloxacin as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Generic Name Levofloxacin (As Hemihydrate) (1 product) · Levofloxacin (as hemihydrate (2 products) · Levofloxacin Tablets Usp 750 Mg (1 product). Products registered under these spellings are included in the table and marked.
All registered products225
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AculevLevofloxacin (as hemihydrate) | 5 mg/mL (500 mg/100 mL) Solution for Intravenous Infusion100 mL LDPE Plastic Bottle (Box of l’s) | Rx | Aculife Healthcare Private LimitedIndia | Blue Global (FZE) | DRP-12348 | Jul 21, 2027 | |
Adolox 500Levofloxacin (as hemihydrate) | 500 mg TabletAlu/Alu Blister Pack x 10 (Box of 10’s) | Rx | Rhydburg Pharmaceuticals Ltd.India | Genedrift Philippines Opc | DRP-18652 | Aug 13, 2031 | |
750mg TabletAlu/Alu Blister Pack x 10 (Box of 10’s) | Rx | Rhydburg Pharmaceuticals Ltd.India | Genedrift Philippines Opc | DRP-18651 | Aug 12, 2031 | ||
Agilevo 500Levofloxacin (as Hemihydrate) | 500 mg Film-Coated TabletAlu/PVC Clear Blister Pack (Box of 5’s) | Rx | Agio Pharmaceuticals LimitedIndia | Labmate Pharma Inc.Importer: Ambica International Corporation | DRP-3135 | Nov 17, 2031 | |
AlevoLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's and 100's) | Rx | Magbro Healthcare Pvt. Ltd.India | Alkem Laboratories CorporationImporter: Pharmakon Biotec Inc. | DRP-5498-04 | Sep 4, 2029 | |
AlevoLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's) | Rx | Alkem Laboratories LimitedIndia | Importer: Alkem Laboratories Corporation | DRP-5632 | Feb 10, 2027 | |
AltolevoLevofloxacin (as hemihydrate) | 750 mg Film-Coated TabletAlu-Alu Foil Strip Pack x 10's (Box of 50's) | Rx | Lloyd Laboratories, Inc.Philippines | Altomed Pharmaceuticals, Inc.Trader: Gamot Philippines, Inc. | DRP-3182-02 | Jul 6, 2031 | |
Ami-LevoLevofloxacin (as hemihydrate) | 500 mg Film–Coated TabletBlister Pack x 5’s (Box of 25’s) | Rx | Zim Laboratories Ltd.India | Pharmasilv TradingImporter: Suhitas Pharmaceuticals Inc.Trader: PSA International (Export Division of PSA Chemicals and Pharmaceuticals Pvt. Ltd.) | DRP-1134-06 | Oct 30, 2028 | |
Ami-levoLevofloxacin (as Hemihydrate) | 750 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Pharmasilv TradingImporter: Ambica International Corporation | DRP-6168 | Nov 28, 2031 | |
AploxinLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's, 50's, and 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.,Philippines | — | DRP-15154 | May 15, 2029 | |
Axa-LevoLevofloxacin (as hemihydrates) | 5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionLDPE plastic bottle x 100 mL (Box of 1’s) | Rx | AXA Parenterals LimitedIndia | Ambica International Corporation | DRP-6473 | Feb 25, 2030 | |
BaxifloxLevofloxacin | 500 mg Film-Coated TabletAlu/Amber PVC Blister Pack x 10's (Box of 40's) | Rx | Centurion Remedies Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | DRP-2627 | Dec 14, 2030 | |
CelevoLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu-Alu blister pack x 10's Box of 30's | Rx | Stallion Laboratories Pvt. Ltd.India | ECE Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-3158-01 | Aug 11, 2029 | |
CelevoLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | ECE Pharmaceuticals, Inc.Importer: Pharmakon Biotec Inc. | DRP-5498-03 | Sep 4, 2029 | |
CevoxineLevofloxacin (as hemihydrate) | 5 mg / mL (500 mg / 100 mL) Solution for IV Infusion100 mL LDPE bottle packed in polypouch (Box of 1's) | Rx | IVM PharmaciaIndia | Pranish Inc. | DRP-16289 | Oct 1, 2029 | |
CevoxineLevofloxacin (as hemihydrate) | 5 mg/mL (500 mg/100 mL) Solution for IV Infusion100 mL LDPE bottle packed in polypouch (Box of 1's) | Rx | IVM PharmaciaIndia | Pranish Inc. | DR-XY49242 | Oct 1, 2029 | |
CevoxineLevofloxacin (as hemihydrate) | 5 mg/mL (500 mg/100 mL) Solution for IV Infusion100 mL LDPE bottle packed in polypouch (Box of 1's) | Rx | IVM PharmaciaIndia | Pranish, Inc. | DRP-17564 | Oct 1, 2029 | |
CrolifarmLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's | Rx | Zim Laboratories Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-4368-01 | Apr 10, 2028 | |
DiafloxcinLevofloxacin (as hemihydrate) | 5 mg/mL (500 mg/100 mL) Solution for Intravenous InfusionLDPE Plastic Bottle in 100 mL | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant III – Injectables)India | Marcburg Philippines Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3937-01 | Sep 4, 2027 | |
ElcinLevofloxacin (as hemihydrate) | 500mg Film-Coated TabletAlu/PVC blister pack x 10's Box of 10's | Rx | SAPPHIRE LIFESCIENCES PVT. LTD.India | 777 Red Pharma IncImporter: Nelpa Lifesciences, Inc. | DRP-8478-01 | May 16, 2027 | |
EvofloxLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/PVDC Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Gamot Philippines, Inc. | DRP-3370 | Nov 9, 2029 | |
EvofloxLevofloxacin (as hemihydrate) | 750 mg Film-Coated TabletAlu-Alu Foil Strip Pack x 10's (Box of 50's) | Rx | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Gamot Philippines, Inc. | DRP-3182 | Nov 19, 2030 | |
Evoxa-500Levofloxacin (As Hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Hiral Labs. Ltd.India | Aglobal Care Inc.Importer: Aglobal Care, Inc. | DRP-11830 | May 20, 2027 | |
FlamidrylLevofloxacin | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 30's) | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DRP-3118 | Nov 18, 2029 | |
FlevLevofloxacin hemihydrate | 500 mg Film-coated tabletAlu/PVC Blister Pack x 10's Box of 30's | Rx | Saga Lifesciences LimitedIndia | Hexagon Pharmaceuticals | DRP-11187 | Sep 15, 2029 | |
Flevoxcin 750Levofloxacin (as Hemihydrate) | 750 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | GX International, Inc.Importer: Ambica International Corporation | DRP-6168-01 | Sep 23, 2037 | |
Flevoxcin IVLevofloxacin (as hemihydrate) | 5 mg/mL (500 mg/100 mL) Solution for Intravenous InfusionLDPE Plastic Bottle in 100 mL | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant III – Injectables)India | GX International, Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3937-03 | Sep 4, 2027 | |
FloxamedLevofloxacin | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's; Box of 100's) | Rx | Ratnatris Pharmaceuticals Private LimitedIndia | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-11525-02 | Mar 31, 2027 | |
FloxanavLevofloxacin | 500 mg Film-Coated TabletAlu/Alu Blister Pack X 10's (Box of 30's and 100's) | Rx | Ratnatris Pharmaceuticals Private LimitedIndia | Jn Carlo Pharmaceuticals DistributorImporter: Medinova Pharmaceutical Inc. | DRP-11525-04 | Mar 31, 2027 | |
FloxanixLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletBlister Pack x 5’s (Box of 25’s) | Rx | Zim Laboratories LimitedIndia | Ranixx PharmaceuticalsImporter: Suhitas Pharmaceuticals Inc.Trader: PSA International (Export Division of PSA Chemicals and Pharmaceuticals Pvt. Ltd.) | DRP-1134-07 | Oct 30, 2028 | |
Floxanova-500Levofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | AMN Life Private LimitedIndia | Medinova Pharmaceutical Inc. | DRP-10249 | Aug 20, 2031 | |
FloxatechLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | One Technodrug Life Sciences Inc.Importer: Pharmakon Biotec Inc. | DRP-5498-05 | Sep 4, 2029 | |
FloxelLevofloxacin (as hemihydrate) | 250 mg/ 50 mL Solution for IV Infusion50 mL USP Type I Clear Glass Vial with rubber Stopper and blue flip-off seal (Box of 1's) | Rx | Amherst Parenterals, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY34503 | Apr 18, 2031 | |
FloxelLevofloxacin (as hydrate) | 5 mg/mL (750 mg/150 mL) Solution for Intravenous Infusion150 mL Type II clear and colorless glass vial sealed with grey rubber closure and orange aluminum cap Box of 1's | Rx | Jeil Pharmaceutical Co., Ltd.Republic of Korea | Importer: UNILAB, Inc. | DR-XY46400 | Jul 31, 2028 | |
FloxelLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletBlister Pack of 10's (Box of 30's) | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY24334 | Aug 6, 2027 | |
FloxelLevofloxacin (As Hemihydrate) | 500 mg/100 mL Solution For IV Infusion100 mL Type I Clear Glass Vial in a box | Rx | Amherst Parenterals, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY27918 | Oct 30, 2027 | |
FloxelLevofloxacin | 750 mg Film-Coated TabletFoil Strip Pack x 4's Box of 20's | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY32172 | Jun 6, 2027 | |
FloxentraLevofloxacin (as hemihydrate) | 5 mg/mL (500 mg /100 mL) Solution for IV Infusion100 mL LDPE Bottle Packed in Polypouch (Box of 1's) | Rx | IVM PharmaciaIndia | Importer: Teramedix Pharma Trading Inc. | DRP-16289-01 | Oct 1, 2029 | |
FloxfatabLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | PSA Chemicals & Pharmaceuticals Pvt. Ltd.India | Blu Med Pharma Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-15147-01 | May 14, 2029 | |
FloxfatabLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Zim Laboratories Ltd.India | Diafarm Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-4368-02 | Apr 10, 2028 | |
FloxilevoLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 7's (Box of 7's) | Rx | Deva Holding A.Ş.Turkey | Endure Medical, Inc. | DR-XY49455 | Jul 18, 2030 | |
Floximed-OdLevofloxacin (As Hemihydrate) | 750 mg Film-Coated TabletALU/ PVC Blister Pack X 10's (Box of 20's and 30's) | Rx | J.M. Tolmann Laboratories Inc.Philippines | Medirich Pharma Distribution Corp. | DRP-3084 | Oct 18, 2030 | |
FloxiprimeLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Primera Pharma CorporationImporter: Ambica International Corporation | DRP-3158 | Aug 11, 2029 | |
FloxlevoLevofloxacin (as hemihydrate) | 5 mg/mL (500 mg/100 mL) Solution for Intravenous InfusionLDPE Plastic Bottle in 100 mL | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant III – Injectables)India | Detoxicare Philippines, Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3937 | Sep 4, 2027 | |
FloxulevLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-9695 | May 5, 2031 | |
FloxwinLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-3158-02 | Aug 11, 2029 | |
GenvoxLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's); Alu/Alu Blister Pack x 10's (Box of 30's) | Rx | Harmann Pharmaceutical Laboratories (PVT) Ltd.Pakistan | Genace Pharma DistributorImporter: Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-9906-03 | Mar 12, 2028 | |
GlevoLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletIndividually boxed blister pack x 5's Box of 25's | Rx | GLENMARK PHARMACEUTICALS LTD.India | Glenmark Philippines, Inc. | DPR-13440 | Jun 23, 2029 | |
GlevoLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletIndividually boxed blister pack x 5's (Box of 25's) | Rx | Glenmark Pharmaceuticals Ltd.India | Glenmark Philippines, Inc. | DRP-17895 | Jun 23, 2029 | |
Glevo I.V.Levofloxacin (as hemihydrates) | 500 mg/100 mL Solution for Infusion (I.V.)LDPE Bottle of 100 mL Box of 1's | Rx | Glenmark Pharmaceuticals Ltd.India | Glenmark Philippines Inc. | DRP-8567 | Jul 3, 2027 | |
GoflexLevofloxacin ( as hemihydrate ) | 750 mg Film Coated TabletAlu/PVC Blister Pack x 10's Box of 50's | Rx | Micro Labs Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Brown & Burk Philippines Inc. | DRP-1010-02 | Jun 3, 2028 | |
Goflox 500Levofloxacin | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's. (Box of 30's; Box of 100's) | Rx | Ratnatris Pharmaceuticals Private LimitedIndia | Applied Pharmaceutical Distribution IncImporter: Medinova Pharmaceutical Inc. | DRP-11525-01 | Mar 31, 2027 | |
I-LexaLevofloxacin | 5 mg/mL Ophthalmic SolutionTranslucent LDPE bottle x 5 mL with translucent LDPE | Rx | Samchundang Pharm Co., Ltd.Korea | Martus Healthcare, Inc. | DRP-17189 | Oct 17, 2031 | |
IfloxLevofloxacin | 5 mg/mL Ophthalmic Solution (Eye Drops)Bottle/Nozzle (Transparent): Low Density Polyethylene; Cap (Pink): High Density Polyethylene | Rx | Unimed Pharm Inc.Republic of Korea | I-Senz Medical Inc. | DR-XY44308 | Mar 19, 2030 | |
Infect-XLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Maple Pharmaceuticals (Pvt.) Ltd.Pakistan | Diafarm Inc.Importer: Ambica International Corporation | DRP-4521-01 | Jul 12, 2028 | |
JazfloxLevofloxacin (as hemihydrate) | 5 mg/mL (0.5% w/v)/100 mL Solution for I.V. InfusionUSP Type 1 Clear Colorless Glass x 100 mL (Box of 1’s) | Rx | Techno Drugs Ltd.1000 Bangladesh | Tamiga Pharmaceuticals SupplyImporter: Bridge Mark Marketing | DRP-3325-01 | Nov 4, 2036 | |
KingfloxinLevofloxacin (as Hemihydrate) | 500 mg/100 mL Solution for IV InfusionClear USP Type I Glass Vial x 100 mL (Box of 1's) | Rx | Geofman PharmaceuticalsPakistan | Sahar International Trading Inc. | DRP-7652 | Oct 25, 2031 | |
LaxinLevofloxacin (As Lactate) | 5 mg/mL (500 mg/100 mL) Solution for IV Infusion100 mL Soda Lime Glass Infusion Bottle (Box of 1's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Aglobal Care, Inc. | DRP-9039 | Aug 18, 2030 | |
LeefloxLevofloxacin (as hemihydrate) | 5 mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drops)LDPE Plastic Dropper tipped bottle x 5 mL (Box of 1's) | Rx | CENTAUR PHARMACEUTICALS PRIVATE LIMITEDIndia | AVANTMED INTERNATIONAL PHARMA INCImporter: STANGEN PHARMACEUTICALS PHILIPPINES INC | DRP-2374 | Aug 5, 2028 | |
LeelaLevofloxacin (as hemihydrate) | 5 mg/mL Solution for IV InfusionWhite translucent Round LDPE Plastic Bottle x 100 mL (Box of 1's) | Rx | Axa Parenterals Ltd.India | Brady Pharma Inc. | DRP-1131 | Feb 28, 2027 | |
LefloxmedLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Curemed Healthcare Pvt. Ltd.India | Ambica International Corporation | DRP-4659 | Sep 2, 2028 | |
LefloxureLevofloxacin (as hemihydrate) | 750 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's | Rx | XL Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-5352 | Jun 20, 2029 | |
LefoxinLevofloxacin (as hemihydrate) | 500 mg / 100 mL Solution for IV Infusion100 mL USP type II Glass vial w/ aluminium seal rubber stopper (Box of 1's); 150 mL USP type II Glass vial w/ aluminium seal rubber stopper (Box of 1's) | Rx | Neutro Pharma (Pvt.) Ltd.Pakistan | Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-17246 | Jul 23, 2027 | |
LefoxinLevofloxacin (As Hemihydrate) | 500 mg/100 mL Solution for IV Infusion100 mL USP Type II glass vial w/ aluminium seal rubber stopper (Box of 1's) 150 mL USP Type II glass vial w/ aluminium seal rubber stopper (Box of 1's) | Rx | Neutro Pharma (Pvt.) Ltd.Pakistan | Raquel-Abbas Pharmaceuticals & General Merchandise | DR-XY38124 | Aug 23, 2027 | |
LegreatLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 5's (Box of 10's and 30's) | Rx | McOlson Research Laboratories (Pvt.) Ltd.Pakistan | Sahar International Trading, Inc. | DRP-7772 | Aug 28, 2028 | |
LenofloxLevofloxacin (as hemihydrate) | 500 mg Film-coated TabletAlu/Alu Blister Pack x 4's (Box of 20's) | Rx | The ACME Laboratories LimitedBangladesh | SEA-King Pharma Inc.Importer: Euro Generics International Philippines Inc. | DRP-1726-02 | May 19, 2029 | |
LenoxaLevofloxacin (as hemihydrate) | 500mg Film-Coated TabletsAlu/PVC/PVDC Blister Pack x 10's (Box of 100's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-14372 | Aug 30, 2028 | |
LevanLevofloxacin | 500 mg Film-Coated TabletPVC-Aluminun Blister Pack x 10's (Box of 30's) | Rx | Hizon Laboratories, Inc.Philippines | Trader: Multicare Pharmaceuticals Philippines, Inc. | DRP-10528 | Sep 25, 2030 | |
LevaxaLevofloxacin | 500 mg/ 100mL Solution for IV Infusion100 mL Polypropylene Bottle (Box of 1's) | Rx | Hebei Tiancheng Pharmaceutical Co., ltd.China | Philrx Pharma Inc. | DRP-10140 | Aug 3, 2031 | |
LevcarLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's); Alu/Alu Blister Pack x 10's (Box of 30's) | Rx | Harmann Pharmaceutical Laboratories (Pvt.) Ltd.Pakistan | Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-9906 | Mar 12, 2028 | |
LEVEFLOX-500LEVOFLOXACIN (as hemihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 5's (Box of 30's); Alu/PVC Blister Pack x 5's (Box of 50's); Alu/PVC Blister Pack x 5's (Box of 100's) | Rx | MEPRO PHARMACEUTICAL PRIVATE LIMITEDIndia | MEEDPHARMA MEDICAL SUPPLIES & EQUIPMENT DISTRIBUTORImporter: MEDETHIX INC. | DRP-6309-02 | Feb 24, 2029 | |
LevfloxLevofloxacin (as Hemihydrate) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Ultramed Pharma, Inc. | DRP-8222 | Oct 8, 2029 | |
LevfloxLevofloxacin (as Hemihydrate) | 750 mg Film-Coated TabletAlu Strip Foil x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Ultramed Pharma, Inc. | DR-XY36767 | Oct 8, 2029 | |
LevfrocineLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Maple Pharmaceuticals (Pvt.) Ltd.Pakistan | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-4521-02 | Jul 12, 2028 | |
LeviflexLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu-PVC Blister Pack x 10's (Box of 30's) | Rx | Unison Pharmaceuticals Pvt. LtdIndia | Euroasia Pharmaceuticals, Inc. | DRP-15858 | Sep 24, 2029 | |
Levin-500Levofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu-PVC Blister Pack x 10's (Box of 100's) | Rx | Hetero Labs Limited (Unit V)India | Camber Pharmaceuticals, Inc. | DRP-8315 | Aug 14, 2031 | |
LevixaLevofloxacin (as hemihydrate) | 500 mg film-coated tabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | Rx | Akriti Pharmaceuticals Pvt. Ltd.India | EuroAsia Pharmaceuticals Inc. | DRP-12672 | Sep 21, 2032 | |
LevixaLevofloxacin (as hemihydrate). | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's and 100's) | Rx | Magbro Healthcare Pvt. Ltd.India | EuroAsia Pharmaceuticals, Inc. | DRP-5498 | Sep 4, 2029 | |
LevobactLevofloxacin ( as hemihydrate ) | 500 mg Film Coated TabletAlu/PVC Blister Pack x 5's (Box of 50's) | Rx | Micro Labs LimitedIndia | Brown & Burk Philippines Inc | DRP-476 | Sep 8, 2028 | |
LevobactLevofloxacin ( as hemihydrate) | 750 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 50's) | Rx | Micro Labs LimitedIndia | Brown & Burk Phils., Inc. | DRP-1010 | Jun 3, 2028 | |
LevobestLevofloxacin | 500 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 30's) | Rx | Zhejiang Medicine Company Limited Xinchang Pharmaceutical FactoryChina | Pharmabest Incorporated | DR-XY48522 | Dec 7, 2027 | |
LevobetLevofloxacin (as hemihydrate) | 500 mg Film – Coated TabletBlister Pack x 5’s (Box of 25’s and 50’s) | Rx | Zim Laboratories LtdIndia | Better Option Pharmaceuticals, Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: PSA International (Export Division of PSA Chemicals and Pharmaceuticals Pvt. Ltd.) | DRP-1134 | Oct 30, 2028 | |
LevobiLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 50's and 30's) | Rx | Baroque Pharmaceuticals Pvt. Ltd.India | Despina Pharma Inc. | DRP-16810 | Jul 15, 2030 | |
LevocentLevofloxacin | 500 mg / 100 mL (0.5% w/v) Solution for I.V. Infusion100 mL LDPE Bottle (Box of 1's) | Rx | Akums Drugs & Pharmaceutical Ltd. (Plant III - Injectables)India | Central West Medicale Inc.Importer: S.M.H.P. Marketing & ConsultancyTrader: Unosource Pharma Ltd. | DRP-10732-01 | Oct 9, 2029 | |
LevocinLevofloxacin (as hemihydrate) | 5 mg/mL (750 mg/ 150 mL) Solution for I.V. InfusionUSP Type II Clear Glass Vial x 150 mL with blue flip- off seal and grey rubber stopper (Box of 1's) | Rx | Getz Pharma (Pvt.), Ltd.Pakistan | Importer: Getz Pharma (Phils.), Inc. | DR-XY41146 | Aug 1, 2030 | |
LevocinLevofloxacin (as hemihydrate) | 5 mg/mL Solution for I.V. InfusionType II USP Clear Vial with Blue Color Flip Off Seal the word "Flip Off" Embossed on top with Off" C Plastic Hanger x 100mL (Box of 1's) | Rx | Getz Pharma (Pvt.), Ltd.Pakistan | Importer: Getz Pharma (Phils.), Inc. | DR-XY37693 | Aug 1, 2030 | |
LevocinLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Getz Pharma (Pvt.), Ltd.Pakistan | Importer: Getz Pharma (Phils.), Inc. | DR-XY42315 | Aug 1, 2030 | |
LevocinLevofloxacin | 750 mg Film-Coated TabletAlu/ Alu Blister Pack x 10's (Box of 10's) | Rx | Getz Pharma (Pvt.), Ltd.Pakistan | Getz Pharma (Phils.); Inc. | DR-XY35773 | Aug 1, 2030 | |
Levoday 750Levofloxacin (as hemihydrate) | 750 mg Film-Coated TabletAlu/white opaque PVC/PVDC blister pack x 10's Box of 100's; Alu/white opaque PVC/PVDC blister pack x 10's Box of 10's as Physician's Sample | Rx | Cadila Healthcare LimitedIndia | Zydus Healthcare Philippines, Inc. | DRP-7898 | Sep 7, 2027 | |
LevofarLevofloxacin (as hemihydrate) | 500 mg Film-CoatedAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Ravian Life Science Pvt. Ltd.India | Pharmakon Biotec Inc. | DRP-5414 | Aug 4, 2029 | |
LevofloxLevofloxacin (as Hemihydrate) | 5 mg/mL Solution for I.V. InfusionUSP Type I glass vial with flip-off seal x 100 mL (Box of 1's) | Rx | L.B.S Laboratory Ltd. Part.Thailand | Phil Pharmawealth, Inc. | DR-XY36508 | Aug 14, 2029 | |
Levofloxin-NatrapharmLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Natrapharm, Inc. | DR-XY36092 | Jul 1, 2029 | |
LevohabLevofloxacin | 500mg/100mL Solution For Infusion (IV)100 mL clear colorless glass vial with dark gray rubber closure and orange aluminum cap (Box of l's) | Rx | Union Korea Pharma Co., Ltd.Korea | H & B Pharma International Inc. | DRP-11556 | Mar 29, 2027 | |
5 mg/mL(500 mg/100 mL) Solution For I.V. InfusionLDPE Blow Molded Plastic Bottle X 100 mL 5 MG/ML (500 MG/100 ML) | Rx | Eurolife Healthcare Pvt. Ltd.India | Medhart Pharma Inc.Importer: Aglobal Care, Inc | DRP-7920 | Jul 25, 2031 | ||
Levolife 500Levofloxacin (as Hemihydrate) | 500 mg Film-Coated TabletAlu/PVC Clear Blister Pack (Box of 5’s) | Rx | Agio Pharmaceuticals LimitedIndia | Altomed Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-3135-02 | Oct 30, 2037 | |
LevoloxLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/PVC/PVDC Clear Blister Pack x 10's (Box of 100's) | Rx | Hizon Laboratories, Inc.Philippines | Sigma Medical Solution Trading Co., Inc. | DRP-513-04 | Sep 9, 2028 | |
Levomac 500Levofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Orange PVC Blister Pack x 20's (Box of 100's); Alu/Orange PVC Blister Pack x 10's (Box of 100's) | Rx | Macleods Pharmaceuticals LimitedIndia | Macleods Pharmaceuticals Philippines, Inc. | DR-XY46987 | Aug 4, 2030 | |
LevomarckLevofloxacin (as hemihydrate) | 5 mg/mL (0.5% w/v) / 100 mL Solution for I.V. InfusionUSP Type 1 Clear Colorless Glass x 100 mL (Box of 1’s) | Rx | Techno Drugs Ltd.Bangladesh | Promarck Pharma and Medical Supplies TradingImporter: Bridgemark Marketing | DRP-3325-02 | Nov 4, 2031 | |
LevomaxLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 4's Box of 20's | Rx | The ACME Laboratories LimitedBangladesh | Euro Generics International Philippines Inc. | DRP-1726 | May 19, 2029 | |
Levomaxin 750Levofloxacin (as Hemihydrate) | 750 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 20's; Box of 100's) | Rx | Rhydburg Pharmaceuticals LimitedIndia | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-8715-02 | Aug 7, 2029 | |
LevomedLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack 10's (Box of 50's) | Rx | Medicraft Pharmaceuticals (Pvt.) Ltd.Pakistan | Geo Pak International Trading Corp. | DR-XY40027 | Sep 8, 2029 | |
LevonatLevofloxacin (as Hemihydrate) | 5 mg/mL Solution for Infusion (I.V.)100 mL and 150 mL Glass Bottle (Box of 1's) | Rx | Yuria - Pharm LtdUkraine | Sannovex Pharmaceutical Distributor | DR-XY45572 | Aug 23, 2031 | |
Levonol-500Levofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Magbro Healthcare Pvt. Ltd.India | NJT EnterprisesImporter: Pharmakon Biotec | DRP-5498-02 | Sep 4, 2029 | |
Levonol-750Levofloxacin (as hemihydrate) | 750 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 5's (Box of 30's) | Rx | Scott-Edil Pharmacia LimitedIndia | NJT EnterprisesImporter: Pharmakon Biotec Inc. | DRP-5974-02 | Mar 11, 2030 | |
Levonova-500Levofloxacin | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Ratnamani Healthcare Pvt. Ltd.India | Medinova Pharmaceutical, Inc. | DRP - 11525 | Mar 31, 2027 | |
LevoprimeLevofloxacin (As Hemihydrate) | 750 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 20's) | Rx | Rhydburg Pharmaceuticals Ltd.India | Medinova Pharmaceutical Inc. | DRP-8715 | Aug 7, 2029 | |
LevoquestLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's); Alu/Alu Blister Pack x 10's (Box of 30's) | Rx | Harmann Pharmaceutical Laboratories (Pvt) Ltd.Pakistan | Health-Quest Pharma and Medical Supplies TradingImporter: Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-9906-02 | Mar 12, 2028 | |
LevoresLevofloxacin (as Hemihydrate) | 5 mg/mL (500 mg/100 mL) Solution for IV InfusionType I Colorless Glass Vial x 100 mL (Box of 1's) | Rx | Pt. Novell Pharmaceutical LaboratoriesIndonesia | Prosweal Healthcare Inc. | DR-XY36754 | Oct 5, 2031 | |
LevoresLevofloxacin (as hemihydrate) | 5 mg/mL (750 mg/15 mL) Solution for IV Infusion.150 mL Polypropylene Soft Bag in a box (Box of 1's) | Rx | PT. Novell Pharmaceutical LaboratoriesIndonesia | Prosweal Healthcare Inc. | DR-XY49147 | Jul 31, 2029 | |
LevosaphLevofloxacin (As Hemihydrate) | 500 mg Fiilm-Coated TabletAlu/PVC Blister pack x 10's (Box of 10's & 100's) | Rx | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-8478 | May 28, 2031 | |
Levosaph-500Levofloxacin (As Hemihydrate) | 5 mg/mL (500 mg/ 100 mL) Solution for IV Infusion100 mL White LDPE Plastic Bottle (Box of 1's) | Rx | Althea Pharma Pvt. Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-13042 | Nov 22, 2027 | |
Levosaph-750Levofloxacin (As Hemihydrate) | 750 mg Film-Coated TabletAlu Clear PVC Blister Pack x 5's & 10's | Rx | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc., | DRP-10956 | May 28, 2031 | |
LevosolLevofloxacin (as hemihydrate) | 5 mg/mL (500 mg/100 mL) Solution for IV InfusionLDPE Bottle x 100 mL (Box of 1's) | Rx | R.K. Laboratories Pvt. Ltd.India | Biocare Lifesciences, Inc. | DRP-18430 | Jul 8, 2031 | |
Levostat 500Levofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu-Alu Blister Pack x 10’s (Box of 30’s and 100's) | Rx | Akriti Pharmaceuticals Pvt. Ltd.India | Genace Pharma DistributorImporter: Aglobal Care Inc.Trader: PPJ Pharma Pvt. Ltd. | DRP-11681 | Aug 14, 2029 | |
Levotab 500Levofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack 5's (Box of 30's and 100's) | Rx | Scott-Edil Pharmacia LimitedIndia | Pharmakon Biotec Inc. | DRP-3921 | Aug 17, 2027 | |
Levotab 750Levofloxacin (as hemihydrate) | 750 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 5's (Box of 30's) | Rx | Scott-Edil Pharmacia LimitedIndia | Pharmakon Biotec Inc. | DRP-5974 | Mar 11, 2030 | |
LevotactLevofloxacin (as hemihydrate) | 500 mg Film–Coated TabletBlister Pack x 5’s (Box of 25’s) | Rx | Zim Laboratories LimitedIndia | Triple Tact Import & Export Corp.Importer: Suhitas Pharmaceuticals Inc.Trader: PSA International (Export Division of PSA Chemicals and Pharmaceuticals Pvt. Ltd.) | DRP-1134-05 | Oct 30, 2028 | |
Levotam-750Levofloxacin (as hemihydrate) | 750 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Maxtar Bio-GenicsIndia | Pharmakon Biotec Inc. | DRP-16471 | Mar 20, 2030 | |
LevoxLevofloxacin (as hemihydrate) | 250 mg/50 mL Solution for I.V. InfusionUSP Type I Clear Glass vial with rubber stopper with blue flip-off seal x 50 mL Box of 1's | Rx | Amherst Parenterals, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY34588 | May 16, 2028 | |
LevoxLevofloxacin (as hemihydrate) | 250 mg/50 mL Solution for IV InfusionUSP Type I Clear Glass vial with rubber stopper with blue flip-off seal x 50 mL (Box of 1's) | Rx | Amherst Parenterals, Inc.Philippines | Trader: UNILAB, Inc. | DRP-14189 | May 16, 2028 | |
LevoxLevofloxacin (As Hemihydrate) | 5 mg/mL (500 mg/100 mL) Solution For Infusion (Iv)100 mL Clear USP Type I Glass Vial with Gray Rubber Stopper & Blue Flip-off Cap | Rx | Amherst Parenterals, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY27919 | Nov 13, 2027 | |
LevoxLevofloxacin (as Hemihydrate) | 5 mg/mL (500 mg/100 mL) Solution for Infusion (IV)100 mL Clear Type I Glass Vial with Gray Rubber Stopper & Blue Flip-Off Cap | Rx | Amherst Parenterals, Inc.Philippines | Trader: UNILAB, Inc. | DRP-14190 | Nov 13, 2027 | |
LevoxLevofloxacin (as hydrate) | 5 mg/mL (750 mg/150 mL) Solution for Intravenous Infusion150 mL Type II clear and colorless glass vial sealed with grey rubber closure and orange aluminum cap (Box of 1's) | Rx | Jeil Pharmaceutical Co., Ltd.Republic of Korea | UNILAB, Inc. | DR-XY46401 | Jul 31, 2028 | |
LevoxLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 40's) | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DRP-13964 | Jun 6, 2027 | |
LevoxLevofloxacin (as hemihydrate) | 500 mg TabletAlu/PVC Blister Pack x 10's Box of 40's | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY23653 | Jun 6, 2027 | |
LevoxLevofloxacin (as hemihydrate) | 750 mg Film-Coated TabletFoil Strip Pack x 4's (Box of 20's) | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY32085 | Jun 6, 2027 | |
LevoxLevofloxacin (as hemihydrate) | 750 mg Film-Coated TabletFoil Strip Pack x 4's (Box of 20's) | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DRP-14188 | Jun 6, 2027 | |
LevoxacLevofloxacin (as Hemihydrate) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 20's) | Rx | The IBN SINA Pharmaceutical Industry Ltd.Bangladesh | Endure Medical Inc. | DR-XY44218 | Feb 26, 2030 | |
LevoxacLevofloxacin (as Hemihydrate) | 750 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 20's) | Rx | The IBN SINA Pharmaceutical Industry Ltd.Bangladesh | Endure Medical Inc. | DR-XY42629 | Sep 13, 2028 | |
LevoxelLevofloxacin (as Hemihydrate) | 5mg/mL (750mg/150mL) Solution For IV InfusionType II clear glass vial with chlorobutyl rubber stopper x 150 mL (Box of l’s) | Rx | Ildong Pharmaceutical Co., Ltd.Korea | International Apex Pharmaceuticals, Inc. | DR-XY47627 | Dec 22, 2026 | |
LevoxinLevofloxacin | 5 mg/mL Solution for InjectionLow Density Polyethylene (LDPE) Bottle in Plastic Pouch x 100 mL (Box of 1's) | Rx | Amanta Healthcare Ltd.India | Endure Medical, Inc. | DR-XY36360 | Jul 29, 2029 | |
Levoxl 750Levofloxacin (as hemihydrate) | 750 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | XL Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-2666 | Feb 7, 2037 | |
LevoxolLevofloxacin (as Hydrochloride) | 100 mg/mL Solution for Injection (IV)Low Borosilicate Ampoule x 2 mL ; Low Borosilicate Ampoule x 3 mL (Box of 10's ; Box of 5's) | Rx | Cisen Pharmaceutical Co., Ltd.China | Endure Medical Inc. | DR-XY43877 | Nov 17, 2029 | |
500 mg Film- Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Akriti Pharmaceuticals Pvt. Ltd.India | Bellus Life Solutions, Inc.Importer: Aglobal Care, Inc | DRP-11681-01 | Aug 14, 2029 | ||
LevoxzanLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Triple 888 Medical And Pharma Inc. | DRP-15154-02 | May 15, 2029 | |
LevozysLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | D & G PharmaImporter: Ambica International Corporation | DRP-3158-04 | Aug 11, 2029 | |
Lexin-ODLevofloxacin (as hemihydrate) | 750 mg Film-Coated TabletAlu-Alu Foil Strip Pack x 10's (Box of 50's) | Rx | Lloyd Laboratories, Inc.Philippines | Medirich Pharma Distribution Corp.Trader: Gamot Philippines, Inc. | DRP-3182-01 | Jul 30, 2031 | |
Lexyl-ODLevofloxacin (as hemihydrate) | 750 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 7's Box of 21's | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DR-XY35960 | Jun 5, 2029 | |
LexzinLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 5’s (Box of 25’s) | Rx | Zim Laboratories LimitedIndia | Starpharm, Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: PSA International (Export Division of PSA Chemicals and Pharmaceuticals Pvt. Ltd.) | DRP-1134-04 | Oct 30, 2028 | |
LEXZINLevofloxacin (as Hemihydrate) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Starpharm, Inc. | DRP-15154-01 | May 15, 2029 | |
LexzinLevofloxacin (as hemihydrates) | 5mg/mL (500mg/100 mL) Solution for I.V InfusionLDPE plastic bottle x 100 mL (Box of 1’s) | Rx | AXA Parenterals LimitedIndia | Starpharm, Inc.Importer: Ambica International Corporation | DRP-6473-01 | Feb 25, 2030 | |
LexzinLevofloxacin (as hemihydrate) | 750 mg Film-Coated TabletAlu/Alu Blister Pack of 10’s (Box of 50’s) | Rx | Agio Pharmaceuticals Ltd.India | Starpharm, Inc.Importer: Ambica International Corporation | DRP-3166 | Oct 18, 2027 | |
Lexzin IVLevofloxacin (as hemihydrate) | 5 mg/mL (500 mg/100 mL) Solution for Intravenous InfusionLDPE Plastic Bottle in 100 mL | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant III – Injectables)India | Starpharm, Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3937-04 | Sep 4, 2027 | |
LotorLevofloxacin (as Hemihydrate) | 500 mg Film Coated TabletBlister Strip x 10's (Box of 50's) | Rx | Emcure Pharmaceuticals Ltd.India | Genpharm, Inc. | DR-XY34495 | Apr 18, 2028 | |
LoxevaLevofloxacin (as hemihydrate) | 5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionClear LDPE Plastic Bottle x 100 mL (Box of 1's) | Rx | Ahlcon Parenterals (India) LimitedIndia | The Cathay Drug Co., Inc.Importer: I.E. Medica, Inc. | DRP-2082-02 | Apr 14, 2028 | |
LoxevaLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAluminum Strip Foil x 10's Box of 30's | Rx | Hizon Laboratories, Inc.Philippines | Trader: The Cathay Drug Co., Inc. | DR-XY37015 | Nov 18, 2029 | |
LoxevaLevofloxacin (as hemihydrate) | 750 mg Film-Coated TabletAlu-Alu Foil Strip Pack x 10's (Box of 50's) | Rx | Lloyd Laboratories, Inc.Philippines | The Cathay Drug Co., Inc.Trader: Gamot Philippines, Inc. | DRP-3182-03 | Nov 19, 2030 | |
750mg Film-Coated TabletCello/Aluminum/Polyethylene Strip Foil x 4's Box of 20’s | Rx | Hizon Laboratories, Inc.Philippines | Trader: The Cathay Drug Co., Inc. | DRP-5178 | Jan 31, 2031 | ||
LquinLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Ravian Life Science Pvt. Ltd.India | Zydus Healthcare Philippines, Inc.Importer: Pharmakon Biotec Inc. | DRP-5414-01 | Aug 4, 2029 | |
MiradenLevofloxacin | 500 mg/100 mL Solution for Intravenous InfusionLDPE FFS Bottle x 100 mL (Box of 1’s) | Rx | Eurolife Healthcare Pvt. Ltd.India | Rifemedica CorporationImporter: Hexagon Pharmaceuticals | DR-XY47206 | Mar 30, 2031 | |
MylevoLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 5's (Box of 10's) | Rx | Domesco Medical Import-Export Joint Stock Corp.Vietnam | JustRight Healthcare Inc. | DRP-3457 | Jan 2, 2027 | |
NoneLevofloxacin (as hemihydrate) | 5 mg/mL (500 mg/100 mL) Solution for Intravenous InfusionLDPE Plastic Bottle in 100 mL | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant III – Injectables)India | International Pharmaceuticals, Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3937-02 | Sep 4, 2027 | |
NoneLevofloxacin (as hemihydrate) | 500 mg Film - Coated TabletAlu/PVC Blister Pack x 10's (Box of 40's) | Rx | Amherst Laboratories, Inc.Philippines | Ritemed Phils., Inc.Trader: UNILAB, Inc. | DRP-13964-01 | Jun 6, 2027 | |
NoneLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | — | DR-XY43195 | Mar 3, 2029 | |
NoneLevofloxacin | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 5’s (Box of 50’s) | Rx | PSA Chemicals & Pharmaceuticals Pvt. Ltd.India | Reta DrugImporter: Suhitas Pharmaceuticals Inc. | DRP-16777-01 | Jul 10, 2030 | |
NoneLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletBlister Pack x 10's (Box of 40's) | Rx | Lek Pharmaceuticals d.d.Slovenia | Watsons Personal Care Stores (Philippines), Inc.Importer: Sandoz Philippines Corporation | DRP-1961-02 | Dec 22, 2027 | |
NoneLevofloxacin (as Hemihydrate) | 500 mg Film-Coated TabletAlu/PVC Clear Blister Pack (Box of 5’s) | Rx | Agio Pharmaceuticals LimitedIndia | International Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-3135-01 | Oct 2, 2037 | |
NoneLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Watsons Personal Care Stores (Philippines), Inc.Importer: Ambica International Corporation | DRP-3158-03 | Aug 11, 2029 | |
NoneLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Sydler Remedies Pvt. Ltd.India | Medethix, Inc.Importer: I.E. Medica, Inc. | DRP-3388-01 | Nov 10, 2029 | |
NoneLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Sydler Remedies Pvt. Ltd.India | Vivilon Pharmaceuticals Inc.Importer: I.E. Medica, Inc. | DRP-3388-02 | Nov 10, 2029 | |
NoneLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Zim Laboratories Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-4368-03 | Apr 10, 2028 | |
NoneLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's | Rx | Zim Laboratories Ltd.India | Actimed, Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-4368-04 | Apr 10, 2028 | |
NoneLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Maple Pharmaceuticals (Pvt.) Ltd.Pakistan | Altomed Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-4521 | Jul 12, 2028 | |
NoneLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/PVC/PVDC Clear Blister Pack x 10's (Box of 30's) | Rx | Hizon Laboratories, Inc.Philippines | Actimed, Inc. | DRP-513-09 | Sep 9, 2028 | |
NoneLevofloxacin (as Hemihydrate) | 500 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's) | Rx | Xl Laboratories Pvt. Ltd.India | Pharex Health CorporationImporter: Ambica International Corporation | DRP-1722-01 | Oct 14, 2031 | |
NoneLevofloxacin (as hemihydrate) | 500 mg/100 mL Solution for IV InfusionUSP Type I Clear Vial x 100 mL (Box of 1's) | Rx | Bosch Pharmaceuticals (Pvt) Ltd.Pakistan | Amson PharmaceuticalsImporter: Sahar International Trading Inc. | DRP-13675-01 | Sep 29, 2029 | |
NoneLevofloxacin (as hemihydrate) | 750 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | XL Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-2666-02 | Mar 12, 2031 | |
NovalevLevofloxacin(As Hemihydrate) | 5mg/mL (500mg/100mL) Solution For Infusion (IV)100 mL Blow-Fill-Seal (BFS)bottle (Box of 1's) | Rx | Unique Pharmaceutical Laboratories (A Division of J.B Chemicals & Pharmaceuticals Ltd.)India | MEDINOVA PHARMACEUTICAL INC | DRP-11833 | May 19, 2027 | |
OcuquinLevofloxacin (as hemihydrate) | 5 mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drops)5 mL LDPE white bottle and clear plug with HDPE white cap (Box of 1's) | Rx | Laboratorios Ashford LDA.China | Marrion Pharma Inc. | DR-XY49795 | Sep 3, 2031 | |
OD-QLevofloxacin (as hemihydrate) | 500 mg Film-coated Tablet.Alu/PVC Blister Pack x 5's (Box of 25's) | Rx | PSA Chemicals & Pharmaceuticals Pvt. Ltd.India | Suhitas Pharmaceuticals Inc. | DRP-16777 | Jul 10, 2030 | |
OftaquixLevofloxacin | 5 mg/mL (0.5 % w/v) Ophthalmic Solution5 mL Bottle (ox of 1's) | Rx | SANTEN PHARMACEUTICAL CO., LTD. (NOTO PLANT)Japan | Importer: Santen Philippines Inc. | DR-XY28881 | Aug 20, 2028 | |
Olcin 750Levofloxacin (as hemihydrate) | 750 mg Film-Coated TabletAlu-PVC Blister Pack x 10's (Box of 10's) | Rx | Delta Pharma Ltd.Bangladesh | Biomed Pharma Inc. | DR-XY40562 | Jan 25, 2030 | |
OMNIVOXLEVOFLOXACIN (as hemihydrate) | 500 mg FILM-COATED TABLETAlu/PVC Blister Pack x 5's (Box of 30's); Alu/PVC Blister pack x 5's (Box of 50's) | Rx | MEPRO PHARMACEUTICALS PRIVATE LIMITEDIndia | BELL-KENZ PHARMA INC.Importer: MEDETHIX INC. | DRP-6309 | Feb 24, 2029 | |
OrafloxLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 50's). | Rx | PSA Chemicals & Pharmaceuticals Pvt. Ltd.India | Orange Biotec Inc. | DRP-15555 | Aug 1, 2029 | |
Q-LevLevofloxacin (as Hemihydrate) | 5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionClear LDPE Plastic Bottle x 100 mL (Box of 1's) | Rx | Ahlcon Parenterals (India) LimitedIndia | Medethix, Inc.Importer: I.E. Medica, Inc. | DRP-2082-03 | Apr 14, 2028 | |
QuifloxLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletClear/PVDC Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Randril International Co., Inc.Trader: Totalcare Pharma Inc. | DR-XY36725 | Sep 29, 2029 | |
QuifloxLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletClear/PVDC Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Randril International Co., Inc.Trader: Totalcare Pharma Inc. | DRP-15624 | Sep 29, 2029 | |
QuifloxLevofloxacin (as hemihydrate) | 750 mg Film-Coated TabletClear/PVDC Blister Pack x 10's Box of 30's | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Totalcare Pharma Inc. | DR-XY36724 | Sep 29, 2029 | |
QuifloxLevofloxacin (as hemihydrate) | 750 mg Film-Coated TabletClear/PVDC Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Totalcare Pharma Inc | DRP-15626 | Sep 29, 2029 | |
Quin-AlonLevofloxacin (as hemihydrate) | 5 mg/mL (250 mg/50 mL) Solution for I.V. Infusion50 mL net content Type I clear and colorless glass vial sealed with a bromobutyl rubber stopper with aluminum | Rx | Pharmathen S.A.Greece | Saifen Drugs Philippines, Inc. | DR-XY49749 | Jun 11, 2031 | |
Quin-Alon 500Levofloxacin (As Hemihydrate) | 500 mg Film-Coated TabletTransparent PVC/PE/PVDC/Aluminum Blister Pack x 10's (Box of 10's) | Rx | Pharmathen SAGreece | Saifen Drugs Philippines Inc. | DR-XY49675 | Mar 18, 2031 | |
Quinogen 500Levofloxacin (as Hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Sydler Remedies Pvt. LimitedIndia | I.E. Medica, Inc. | DRP-3388 | Nov 10, 2029 | |
QuinolevLevofloxacin (as Hemihydrate) | 5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionClear LDPE Plastic Bottle x 100 mL (Box of 1's) | Rx | Ahlcon Parenterals (India) Ltd.India | I.E. Medica, Inc. | DRP-2082 | Apr 14, 2028 | |
QuinoplusLevofloxacin (as hemihydrate) | 5 mg/mL Solution for IV infusionPolypropylene monochamber bag (wrapped in aluminum pouch) x 100 mL (Box of 4's and 20's) and 150mL (Box of 4's and 10's) | Rx | — | Medlink Marketing | DR-XY46107 | Oct 19, 2027 | |
QuixlevLevofloxacin (As Hemihydrate) | 500 mg Film-Coated TabletAlu/PVDC Blister Pack x 10's (Box of 20's and 30's) | Rx | J.M. Tolmann Laboratories, Inc.Philippines | Medirich Pharma Distribution Corp.Trader: Westfield Pharmaceuticals, Inc. | DR-XY39709 | Jul 1, 2031 | |
RemediaLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's and 100's) | Rx | Simpex Pharma Pvt. Ltd.India | Pharmastar Int'l Trading Corp. | DRP-7087 | Apr 25, 2031 | |
ResfloxLevofloxacin (as hemihydrate) | 500 mg/100 mL Solution for IV InfusionLDPE White Transparent Bottle x 100 mL (Box of 1's) | Rx | Albert David LimitedIndia | Medethix, Inc. | DRP-7928 | Jul 24, 2028 | |
RetafloxelLevofloxacin | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's; Box of 100's) | Rx | Ratnatris Pharmaceuticals Private LimitedIndia | Reta DrugImporter: Medinova Pharmaceutical Inc. | DRP-11525-03 | Mar 31, 2027 | |
RumafloxLevofloxacin (as Hemihydrate) | 500 mg Film-Coated TabletAlu/ Alu Blister Pack x 10's Box of 50's | Rx | Medisure Laboratories Pakistan (Pvt.) LimitedPakistan | Accesspoint International Trading Inc. | DRP-5843 | Dec 1, 2029 | |
SantisLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletBlister Pack x 10's (Box of 40's) | Rx | Lek Pharmaceuticals d.d.Slovenia | Sandoz Philippines Corporation | DRP-1961 | Dec 22, 2027 | |
SerlevLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's & 100's) | Rx | The Searle Company LimitedPakistan | Britton Distributions, Inc. | DRP-5331 | Jun 2, 2029 | |
SITI-vouxLevofloxacin (as hemihydrate) | 500 mg/100 mL Solution for IV InfusionUSP Type I Clear Glass Vial x 100 mL (Box of 1's) | Rx | Bosch Pharmaceuticals (Pvt.) Ltd.Pakistan | Sahar International Trading Inc. | DRP-13675 | Sep 29, 2029 | |
StarlevLevofloxacin (as hemihydrate) | 5 mg/mL (500 mg/100 mL) Solution for I.V. Infusion100 mL USP Type II clear glass vial with 32 mm flip- off seal and opaque grey rubber stopper (Box of 1's) | Rx | Indus Pharma (Pvt.) Ltd.Pakistan | One Dexcel Pharma Inc. | DRP-13563 | Mar 9, 2028 | |
SuquinLevofloxacin (as Hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 50’s) | Rx | Stallion Laboratories Pvt. Ltd.India | Suhitas Pharmaceuticals, Inc.Trader: Mac Heal Laboratories Ltd. | DRP-3307 | Oct 12, 2031 | |
SuquinLevofloxacin (as Hemihydrate) | 750 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s Box of 50’s | Rx | Stallion Laboratories Pvt. Ltd.India | Suhitas Pharmaceuticals Inc.Trader: Mac Heal Laboratories Ltd. | DRP-3308 | Oct 12, 2031 | |
SydenvoxLevofloxacin (as hemihydrate) | 500 mg Film Coated TabletAlu-PVC Blister x 10's (Box of 40's) | Rx | Sydenham Laboratories, Inc.Philippines | — | DRP-15931 | Oct 2, 2029 | |
SydenvoxLevofloxacin (as hemihydrate) | 750 mg Film Coated TabletAlu-PVC Blister x 10's (Box of 20's) | Rx | Sydenham Laboratories, Inc.Philippines | — | DRP-15932 | Oct 2, 2029 | |
TelevoLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | PSA Chemicals & Pharmaceuticals Pvt. Ltd.India | Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-15147 | May 14, 2029 | |
TelevoLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's | Rx | Zim Laboratories Ltd.India | Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP4368 | Apr 10, 2028 | |
TeralevLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Ravian Life Science Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-5414-02 | Aug 4, 2029 | |
TeravoxLevofloxacin (as Hemihydrate) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | Rx | Drugmaker's Laboratories, Inc.Philippines | Trader: Terramedic, Inc. | DR-XY40485 | Jan 2, 2032 | |
TerlevLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 5's (Box of 50's) | Rx | Micro Labs LimitedIndia | ADP Pharma CorporationImporter: Brown & Burk Philippines, Inc. | DRP-476-01 | Sep 8, 2028 | |
Tigeron 500Levofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 5's (Box of 5's and 50's); Alu/PVC/PVDC Blister Pack x 10's (Box of 10's and 50's) | Rx | Kusum Healthcare Private LimitedIndia | Kusum Healthcare Private Limited Branch Office | DRP-11815 | May 6, 2030 | |
Tigeron 750®Levofloxacin (as hemihydrate) | 750 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 5's (Box of 5's and 50’s); Alu/PVC/PVDC Blister Pack x 10’s (Box of 10’s and 50’s) | Rx | Kusum Healthcare Private LimitedIndia | Kusum Healthcare Private Limited Branch Office | DRP-10503 | May 6, 2030 | |
TrulevLevofloxacin | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 30's) | Rx | Flamingo Pharmaceuticals Ltd.India | Trumed PharmaceuticalsImporter: Hexagon Pharmaceuticals | DRP-3118-01 | Nov 18, 2029 | |
UnbrandedLevofloxacin (as Hemihydrate) | 500 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's) | Rx | XL LABORATORIES PVT. LTD.India | Pharex Health CorporationImporter: Ambica International Corporation | DRP-1722 | Nov 23, 2031 | |
UnbrandedLevofloxacin (as hemihydrate) | 750 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 50’s) | Rx | Agio Pharmaceuticals Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Ambica International Corporation | DRP-3166-01 | Oct 18, 2027 | |
UnbrandedLevofloxacin (as hemihydrate) | 750 mg Film-Coated TabletAlu-Clear PVC Blister Pack x 10’s (Box of 30’s) | Rx | Hizon Laboratories, Inc.Rizal | — | DRP-4036 | Oct 28, 2031 | |
Urilev I.V.Levofloxacin (as hemihydrate) | 5 mg/mL (0.5% w/v) Solution for I.V. InfusionUSP Type 1 Clear Colorless Glass x 100 mL (Box of 1's) | Rx | Techno Drugs Ltd.Bangladesh | Jazmark PharmaceuticalImporter: Bridgemark Marketing | DRP-3325 | Nov 4, 2031 | |
VofloxLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAluminum/Clear PVDC Blister Pack x 10's (Box of 30's and 100's) | Rx | Sai Mirra Innopharm Pvt., Ltd.India | Eon Pharmatek, Inc. | DR-XY36696 | Sep 29, 2029 | |
Voflox-750Levofloxacin (as hemihydrate) | 750 mg Film-coated TabletAlu/Alu Blister Pack x 10's Box of 100's | Rx | Sai Mirra Innopharm Pvt. Ltd.India | Eon Pharmatek, Inc. | DR-XY46719 | Sep 18, 2029 | |
VolecaLevofloxacin (as hemihydrate) | 5 mg/mL (500mg/100mL) Solution for Intravenous Infusion100mL Ph. Eur. Type II clear and colorless glass vial with bromobutyl rubber stopper and flip-off seal (Box of 1's) | Rx | PT Ferron Par PharmaceuticalsIndonesia | Importer: Glorious Dexa Mandaya, Inc.Trader: PT Dexa Medica | DR-XY46168 | Nov 24, 2027 | |
VolecaLevofloxacin (as hemihydrate) | 5 mg/mL (500mg/100mL) Solution for Intravenous Infusion100mL Ph. Eur. Type II Clear and Colorless Glass Vial with Bromobutyl Rubber Stopper and Flip-off Seal (Box of 1's) | Rx | PT Ferron Par PharmaceuticalsIndonesia | Importer: Glorious Dexa Mandaya, Inc.Trader: PT Dexa Medica | DRP-12621 | Nov 24, 2027 | |
VolecaLevofloxacin | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's) | Rx | PT. Dexa MedicaIndonesia | Glorious Dexa Mandaya, Inc. | DRP-8078 | Aug 10, 2029 | |
VolecaLevofloxacin (as Hemihydrate) | 750 mg/150 mL Solution for IV InfusionIn 250 mL-capacity USP Type II Clear Glass Bottle x 150 mL with Grey Bromobutyl Rubber Stopper and Flip-Off Aluminum Seal (Box of 1's) | Rx | PT FERRON PAR PHARMACEUTICALSIndonesia | GLORIOUS DEXA MANDAYA, INC.Trader: PT DEXA MEDICA | DRP-8428 | Aug 16, 2028 | |
VoxelacinLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-9695-01 | Jul 30, 2031 | |
WelquineLevofloxacin | 500 mg/100 mL (0.5% w/v) Solution for I.V. Infusion100 mL LDPE Bottle Box of 1's | Rx | Akums Drugs & Pharmaceutical Ltd. (Plant III - Injectables)India | S.M.H.P. Marketing & ConsultancyTrader: Unosource Pharma Ltd. | DRP-10732 | Oct 9, 2029 | |
WilovexLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/PVC/PVDC Clear Blister Pack x 10's (Box of 30's and 100's) | Rx | Hizon Laboratories, Inc.Philippines | Willore Pharma Corporation | DRP-513 | Sep 9, 2028 | |
WilovexLevofloxacin (as hemihydrate) | 500 mg/100 mL Solution for IV InfusionUSP Type I clear glass vial with blue flip-off seal x 100 mL (Box of 1's) | Rx | Hizon Laboratories, Inc.Philippines | Trader: Willore Pharma Corporation | DR-XY47023 | Oct 20, 2030 | |
WinafloxLevofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu/PVC/PVDC Clear Blister Pack x 10's Box of 30's | Rx | Hizon Laboratories, Inc.Philippines | Pharma Dynamic, Inc. | DRP-513-10 | Sep 9, 2028 | |
XovellLevofloxacin hemihydrate | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's Box of 30's | Rx | Saga Lifesciences LimitedIndia | Primedrug Marketing CorporationImporter: Hexagon Pharmaceuticals | DRP-11187-01 | Sep 15, 2029 | |
ZoquinLevofloxacin (as hemihydrate) | 5 mg/mL Solution for Intravenous InfusionUSP Type II clear and colorless glass vial sealed with gray rubber closure and blue aluminum flip-off seal x 100 mL (Box of 1's) | Rx | Baxter Pharmaceuticals India Private LimitedIndia | Baxter Healthcare Philippines Inc | DR-XY46425 | Sep 27, 2028 | |
(no brand name)Levofloxacin(As Hemihydrate) | 5 mg/mL (500 mg/100 mL) Solution for IV Infusion100 mL LDPE Bottle fitted with dust cap (Box of 1’s) | Rx | Ahlcon Parenterals (India) LimitedIndia | Medinova Pharmaceutical Inc. | DRP-11822 | May 16, 2027 | |
(no brand name)Levofloxacin (As Hemihydrate) | 500 MG Film - Coated TabletBlister Foil x 10's (Box of 100's) | Rx | Ranbaxy (Malaysia) SDN. HBD.Malaysia | RiteMED Phils., Inc. | DRP-1414 | Jul 19, 2028 | |
(no brand name)Levofloxacin (as hemihydrate) | 500 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | Rx | Akriti Pharmaceuticals Pvt. Ltd.India | TGP Pharma Inc.Importer: Aglobal Care, Inc. | DRP-11681-02 | Aug 14, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Levofloxacin tablets USP, 250 mg are terra pink colored capsule shaped, biconvex film-coated tablets, debossed with ‘13’ on one side and ‘T’ on the other side. Levofloxacin tablets USP, 500 mg are peach colored capsule shaped, biconvex film-coated tablets, debossed with ‘12’ on one side and ‘T’ on the other side. Levofloxacin tablets USP, 750 mg are white capsule shaped, biconvex film-coated tablets, debossed with ‘11’ on one side and ‘T’ on the other side. Tablets: 250 mg, 500 mg, and 750 mg
Warnings/Precautions
The boxed warning is shown at the top of this page.
- Anaphylactic reactions and allergic skin reactions, serious, occasionally fatal, may occur after first dose (4, 5.7) Hematologic (including agranulocytosis, thrombocytopenia), and renal toxicities may occur after multiple doses (5.6)
- Hepatotoxicity: Severe, and sometimes fatal, hepatotoxicity has been reported. Discontinue immediately if signs and symptoms of hepatitis occur (5.8)
- Clostridium difficile -associated colitis: evaluate if diarrhea occurs (5.10)
- Prolongation of the QT interval and isolated cases of torsade de pointes have been reported. Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval (5.11, 8.5)
5.1 Disabling and Potentially Irreversible Serious Adverse Reactions Including Tendinitis and…
5.1 Disabling and Potentially Irreversible Serious Adverse Reactions Including Tendinitis and Tendon Rupture, Peripheral Neuropathy, and Central Nervous System Effects Fluoroquinolones, including levofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions from different body systems that can occur together in the same patient. Commonly seen adverse reactions include tendinitis, tendon rupture, arthralgia, myalgia, peripheral neuropathy, and central nervous system effects (hallucinations, anxiety, depression, insomnia, severe headaches, and confusion).
These reactions can occur within hours to weeks after starting levofloxacin. Patients of any age or without pre-existing risk factors have experienced these adverse reactions [see Warnings and Precautions (5.2, 5.3, 5.4)]. Discontinue levofloxacin immediately at the first signs or symptoms of any serious adverse reaction.
In addition, avoid the use of fluoroquinolones, including levofloxacin, in patients who have experienced any of these serious adverse reactions associated with fluoroquinolones.
5.2 Tendinitis and Tendon Rupture
5.2 Tendinitis and Tendon Rupture Fluoroquinolones, including levofloxacin, have been associated with an increased risk of tendinitis and tendon rupture in all ages [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)]. This adverse reaction most frequently involves the Achilles tendon and has also been reported with the rotator cuff (the shoulder), the hand, the biceps, the thumb, and other tendon sites.
Tendinitis or tendon rupture can occur within hours or days of starting levofloxacin or as long as several months after completion of fluoroquinolone therapy. Tendinitis and tendon rupture can occur bilaterally. The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants.
Other factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis. Tendinitis and tendon rupture have been reported in patients taking fluoroquinolones who do not have the above risk factors. Discontinue levofloxacin immediately if the patient experiences pain, swelling, inflammation or rupture of a tendon.
Patients should be advised to rest at the first sign of tendinitis or tendon rupture, and to contact their healthcare provider regarding changing to a non-quinolone antimicrobial drug. Avoid levofloxacin in patients who have a history of tendon disorders or tendon rupture [see Adverse Reactions (6.2) and Patient Counseling Information (17)].
5.3 Peripheral Neuropathy
5.3 Peripheral Neuropathy Fluoroquinolones, including levofloxacin, have been associated with an increased risk of peripheral neuropathy. Cases of sensory or sensorimotor axonal polyneuropathy affecting small and/or large axons resulting in paresthesias, hypoesthesias, dysesthesias and weakness have been reported in patients receiving fluoroquinolones, including levofloxacin.
Symptoms may occur soon after initiation of levofloxacin and may be irreversible in some patients [see Warnings and Precautions (5.1) and Adverse Reactions (6, 6.1)]. Discontinue levofloxacin immediately if the patient experiences symptoms of neuropathy including pain, burning, tingling, numbness, and/or weakness or other alterations of sensation including light touch, pain, temperature, position sense, and vibratory sensation.
Avoid fluoroquinolones, including levofloxacin, in patients who have previously experienced peripheral neuropathy [see Adverse Reactions (6) and Patient Counseling Information (17)].
5.4 Central Nervous System Effects Psychiatric Adverse Reactions
5.4 Central Nervous System Effects Psychiatric Adverse Reactions Fluoroquinolones, including levofloxacin, have been associated with an increased risk of psychiatric adverse reactions, including: toxic psychoses, hallucinations, or paranoia; depression, or suicidal thoughts; anxiety, agitation, restlessness, or nervousness; confusion, delirium, disorientation, or disturbances in attention; insomnia or nightmares; memory impairment. Attempted or completed suicide have been reported, especially in patients with a medical history of depression, or an underlying risk factor for depression.
These reactions may occur following the first dose. If these reactions occur in patients receiving levofloxacin, discontinue levofloxacin and institute appropriate measures. Central Nervous System Adverse Reactions Fluoroquinolones, including levofloxacin, have been associated with an increased risk of seizures (convulsions), increased intracranial pressure (including pseudotumor cerebri), tremors, and lightheadedness.
As with other fluoroquinolones, levofloxacin should be used with caution in patients with a known or suspected central nervous system (CNS) disorder that may predispose them to seizures or lower the seizure threshold (e.g., severe cerebral arteriosclerosis, epilepsy) or in the presence of other risk factors that may predispose them to seizures or lower the seizure threshold (e.g., certain drug therapy, renal dysfunction). If these reactions occur in patients receiving levofloxacin, discontinue levofloxacin and institute appropriate measures [see Adverse Reactions (6), Drug Interactions (7.4, 7.5), and Patient Counseling Information (17)].
5.5 Exacerbation of Myasthenia Gravis
5.5 Exacerbation of Myasthenia Gravis Fluoroquinolones, including levofloxacin, have neuromuscular blocking activity and may exacerbate muscle weakness in patients with myasthenia gravis. Postmarketing serious adverse reactions including deaths and requirement for ventilatory support, have been associated with fluoroquinolone use in patients with myasthenia gravis.
Avoid levofloxacin in patients with a known history of myasthenia gravis [see Adverse Reactions (6.2) and Patient Counseling Information (17)].
5.6 Other Serious and Sometimes Fatal Adverse Reactions
5.6 Other Serious and Sometimes Fatal Adverse Reactions Other serious and sometimes fatal adverse reactions, some due to hypersensitivity, and some due to uncertain etiology, have been reported rarely in patients receiving therapy with fluoroquinolones, including levofloxacin. These events may be severe and generally occur following the administration of multiple doses.
Clinical manifestations may include one or more of the following: fever, rash, or severe dermatologic reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome); vasculitis; arthralgia; myalgia; serum sickness; allergic pneumonitis; interstitial nephritis; acute renal insufficiency or failure; hepatitis; jaundice; acute hepatic necrosis or failure; anemia, including hemolytic and aplastic; thrombocytopenia, including thrombotic thrombocytopenic purpura; leukopenia; agranulocytosis; pancytopenia; and/or other hematologic abnormalities. Discontinue levofloxacin immediately at the first appearance of skin rash, jaundice, or any other sign of hypersensitivity and institute supportive measures [see Adverse Reactions (6) and Patient Counseling Information (17)].
5.7 Hypersensitivity Reactions
5.7 Hypersensitivity Reactions Serious and occasionally fatal hypersensitivity and/or anaphylactic reactions have been reported in patients receiving therapy with fluoroquinolones, including levofloxacin. These reactions often occur following the first dose. Some reactions have been accompanied by cardiovascular collapse, acute myocardial ischemia with or without myocardial infarction, hypotension/shock, seizure, loss of consciousness, tingling, angioedema (including tongue, laryngeal, throat, orfacial edema/swelling), airway obstruction (including bronchospasm, shortness of breath, and acute respiratory distress), dyspnea, urticaria, itching, and other serious skin reactions.
Levofloxacin should be discontinued immediately at the first appearance of a skin rash or any other sign of hypersensitivity. Serious acute hypersensitivity reactions may require treatment with epinephrine and other resuscitative measures, including oxygen, intravenous fluids, antihistamines, corticosteroids, pressor amines, and airway management, as clinically indicated [see Adverse Reactions (6) and Patient Counseling Information (17)].
5.8 Hepatotoxicity
5.8 Hepatotoxicity Post-marketing reports of severe hepatotoxicity (including acute hepatitis and fatal events) have been received for patients treated with levofloxacin. No evidence of serious drug-associated hepatotoxicity was detected in clinical trials of over 7,000 patients. Severe hepatotoxicity generally occurred within 14 days of initiation of therapy and most cases occurred within 6 days.
Most cases of severe hepatotoxicity were not associated with hypersensitivity [see Warnings and Precautions (5.6)]. The majority of fatal hepatotoxicity reports occurred in patients 65 years of age or older and most were not associated with hypersensitivity. Levofloxacin should be discontinued immediately if the patient develops signs and symptoms of hepatitis [see Adverse Reactions (6) and Patient Counseling Information (17)].
5.9 Risk of Aortic Aneurysm and Dissection
5.9 Risk of Aortic Aneurysm and Dissection Epidemiologic studies report an increased rate of aortic aneurysm and dissection within two months following use of fluoroquinolones, particularly in elderly patients. The cause for the increased risk has not been identified. In patients with a known aortic aneurysm or patients who are at greater risk for aortic aneurysms, reserve levofloxacin for use only when there are no alternative antibacterial treatments available.
5.10 Clostridium difficile
5.10 Clostridium difficile -Associated Diarrhea Clostridium difficile -associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including levofloxacin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use.
Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated [see Adverse Reactions (6.1) and Patient Counseling Information (17)].
5.11 Prolongation of the QT Interval
5.11 Prolongation of the QT Interval Some fluoroquinolones, including levofloxacin, have been associated with prolongation of the QT interval on the electrocardiogram and infrequent cases of arrhythmia. Rare cases of torsade de pointes have been spontaneously reported during postmarketing surveillance in patients receiving fluoroquinolones, including levofloxacin.
Levofloxacin should be avoided in patients with known prolongation of the QT interval, patients with uncorrected hypokalemia, and patients receiving Class IA (quinidine, procainamide), or Class III (amiodarone, sotalol) antiarrhythmic agents. Elderly patients may be more susceptible to drug-associated effects on the QT interval [see Adverse Reactions (6.2), Use in Specific Populations (8.5), and Patient Counseling Information (17)].
5.12 Musculoskeletal Disorders in Pediatric Patients and Arthropathic Effects in Animals
5.12 Musculoskeletal Disorders in Pediatric Patients and Arthropathic Effects in Animals Levofloxacin is indicated in pediatric patients (6 months of age and older) only for the prevention of inhalational anthrax (post-exposure) and for plague [see Indications and Usage (1.7, 1.8)]. An increased incidence of musculoskeletal disorders (arthralgia, arthritis, tendinopathy, and gait abnormality) compared to controls has been observed in pediatric patients receiving levofloxacin [see Use in Specific Populations (8.4)].
In immature rats and dogs, the oral and intravenous administration of levofloxacin resulted in increased osteochondrosis. Histopathological examination of the weight-bearing joints of immature dogs dosed with levofloxacin revealed persistent lesions of the cartilage. Other fluoroquinolones also produce similar erosions in the weight-bearing joints and other signs of arthropathy in immature animals of various species [see Animal Toxicology and/or Pharmacology (13.2)].
5.13 Blood Glucose Disturbances
5.13 Blood Glucose Disturbances Fluoroquinolones, including levofloxacin, have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. In these patients, careful monitoring of blood glucose is recommended.
Severe cases of hypoglycemia resulting in coma or death have been reported. If a hypoglycemic reaction occurs in a patient being treated with levofloxacin, discontinue levofloxacin and initiate appropriate therapy immediately [see Adverse Reactions (6.1), Drug Interactions (7.3) and Patient Counseling Information (17)].
5.14 Photosensitivity/Phototoxicity
5.14 Photosensitivity/Phototoxicity Moderate to severe photosensitivity/phototoxicity reactions, the latter of which may manifest as exaggerated sunburn reactions (e.g., burning, erythema, exudation, vesicles, blistering, edema) involving areas exposed to light (typically the face, “V” area of the neck, extensor surfaces of the forearms, dorsa of the hands), can be associated with the use of fluoroquinolones after sun or UV light exposure. Therefore, excessive exposure to these sources of light should be avoided.
Drug therapy should be discontinued if photosensitivity/phototoxicity occurs [see Adverse Reactions (6.2) and Patient Counseling Information (17)].
5.15 Development of Drug Resistant Bacteria
5.15 Development of Drug Resistant Bacteria Prescribing levofloxacin in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria [see Patient Counseling Information (17)].
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Multivalent cations: Mg/Al antacids, sucralfate, iron, zinc multivitamins, didanosine | Adjust or monitor | Lower levofloxacin absorption. | Give these at least 2 hours before or 2 hours after levofloxacin. |
| Warfarin | Adjust or monitor | Enhanced effect and bleeding (postmarketing). | Monitor PT/INR closely and watch for bleeding. |
| Antidiabetic agents | Adjust or monitor | Hyperglycemia and hypoglycemia. | Monitor blood glucose carefully. |
| QT-prolonging drugs (class IA/III antiarrhythmics, others) | Avoid | Additive QT prolongation, torsades de pointes. | Avoid; correct potassium and magnesium. |
| NSAIDs | Adjust or monitor | CNS stimulation and seizures. | Use with caution. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewed- Interacting Drug Interaction Multivalent cation-containing products including antacids, metal cations or didanosine Absorption of levofloxacin is decreased when the tablets are taken within 2 hours of these products. (2.4, 7.1)
- Warfarin Effect may be enhanced. Monitor prothrombin time, INR and watch for bleeding (7.2)
- Antidiabetic agents Carefully monitor blood glucose (5.13, 7.3)
7.1 Chelation Agents
7.1 Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of levofloxacin tablets with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. Tablets with antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc or didanosine may substantially interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired.
These agents should be taken at least two hours before or two hours after oral levofloxacin administration.
7.2 Warfarin
7.2 Warfarin No significant effect of levofloxacin on the peak plasma concentrations, AUC, and other disposition parameters for R- and S- warfarin was detected in a clinical study involving healthy volunteers. Similarly, no apparent effect of warfarin on levofloxacin absorption and disposition was observed. However, there have been reports during the postmarketing experience in patients that levofloxacin enhances the effects of warfarin.
Elevations of the prothrombin time in the setting of concurrent warfarin and levofloxacin use have been associated with episodes of bleeding. Prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests should be closely monitored if levofloxacin is administered concomitantly with warfarin.
Patients should also be monitored for evidence of bleeding [see Adverse Reactions (6.2) and Patient Counseling Information (17)].
7.3 Antidiabetic Agents
7.3 Antidiabetic Agents Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with fluoroquinolones and an antidiabetic agent. Therefore, careful monitoring of blood glucose is recommended when these agents are co-administered [see Warnings and Precautions (5.13), Adverse Reactions (6.1), and Patient Counseling Information (17)].
7.4 Non-Steroidal Anti-Inflammatory Drugs
7.4 Non-Steroidal Anti-Inflammatory Drugs The concomitant administration of a non-steroidal anti-inflammatory drug with a fluoroquinolone, including levofloxacin, may increase the risk of CNS stimulation and convulsive seizures [see Warnings and Precautions (5.4)].
7.5 Theophylline
7.5 Theophylline No significant effect of levofloxacin on the plasma concentrations, AUC, and other disposition parameters for theophylline was detected in a clinical study involving healthy volunteers. Similarly, no apparent effect of theophylline on levofloxacin absorption and disposition was observed. However, concomitant administration of other fluoroquinolones with theophylline has resulted in prolonged elimination half-life, elevated serum theophylline levels, and a subsequent increase in the risk of theophylline-related adverse reactions in the patient population.
Therefore, theophylline levels should be closely monitored and appropriate dosage adjustments made when levofloxacin is co-administered. Adverse reactions, including seizures, may occur with or without an elevation in serum theophylline levels [see Warnings and Precautions (5.4)].
7.6 Cyclosporine
7.6 Cyclosporine No significant effect of levofloxacin on the peak plasma concentrations, AUC, and other disposition parameters for cyclosporine was detected in a clinical study involving healthy volunteers. However, elevated serum levels of cyclosporine have been reported in the patient population when co-administered with some other fluoroquinolones.
Levofloxacin C max and k e were slightly lower while T max and t ½ were slightly longer in the presence of cyclosporine than those observed in other studies without concomitant medication. The differences, however, are not considered to be clinically significant. Therefore, no dosage adjustment is required for levofloxacin or cyclosporine when administered concomitantly.
7.7 Digoxin
7.7 Digoxin No significant effect of levofloxacin on the peak plasma concentrations, AUC, and other disposition parameters for digoxin was detected in a clinical study involving healthy volunteers. Levofloxacin absorption and disposition kinetics were similar in the presence or absence of digoxin. Therefore, no dosage adjustment for levofloxacin or digoxin is required when administered concomitantly.
7.8 Probenecid and Cimetidine
7.8 Probenecid and Cimetidine No significant effect of probenecid or cimetidine on the C max of levofloxacin was observed in a clinical study involving healthy volunteers. The AUC and t 1/2 of levofloxacin were higher while CL/F and CL R were lower during concomitant treatment of levofloxacin with probenecid or cimetidine compared to levofloxacin alone.
However, these changes do not warrant dosage adjustment for levofloxacin when probenecid or cimetidine is co-administered.
7.9 Interactions with Laboratory or Diagnostic Testing
7.9 Interactions with Laboratory or Diagnostic Testing Some fluoroquinolones, including levofloxacin, may produce false-positive urine screening results for opiates using commercially available immunoassay kits. Confirmation of positive opiate screens by more specific methods may be necessary.
Adverse reactions
Common
- Nausea, headache, diarrhea, insomnia, constipation, dizziness (≥3%)
Serious
- Tendinitis and tendon rupture (boxed warning)
- Peripheral neuropathy (boxed warning)
- Central nervous system and psychiatric effects (boxed warning)
- Exacerbation of myasthenia gravis (boxed warning)
- Hypersensitivity and other serious reactions
- Clostridium difficile-associated diarrhea
- QT prolongation
- Blood glucose disturbances
- Photosensitivity
- Aortic aneurysm and dissection
The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling: Disabling and Potentially Irreversible Serious Adverse Reactions [see Warnings and Precautions (5.1)] Tendinitis and Tendon Rupture [see Warnings and Precautions (5.2)] Peripheral Neuropathy [see Warnings and Precautions (5.3)] Central Nervous System Effects [see Warnings and Precautions (5.4)] Exacerbation of Myasthenia Gravis [see Warnings and Precautions (5.5)] Other Serious and Sometimes Fatal Reactions [see Warnings and Precautions (5.6)] Hypersensitivity Reactions [see Warnings and Precautions (5.7)] Hepatotoxicity [see Warnings and Precautions (5.8)] Risk of Aortic Aneurysm and Dissection [see Warnings and Precautions (5.9)] Clostridium difficile -Associated Diarrhea [see Warnings and Precautions (5.10)] Prolongation of the QT Interval [see Warnings and Precautions (5.11)] Musculoskeletal Disorders in Pediatric Patients [see Warnings and Precautions (5.12)] Blood Glucose Disturbances [see Warnings and Precautions (5.13)] Photosensitivity/Phototoxicity [see Warnings and Precautions (5.14)] Development of Drug Resistant Bacteria [see Warnings and Precautions (5.15)] Crystalluria and cylindruria have been reported with quinolones, including levofloxacin. Therefore, adequate hydration of patients receiving levofloxacin should be …
6.1 Clinical Trial Experience
6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described below reflect exposure to levofloxacin in 7537 patients in 29 pooled Phase 3 clinical trials.
The population studied had a mean age of 50 years (approximately 74% of the population was < 65 years of age), 50% were male, 71% were Caucasian, 19% were Black. Patients were treated with levofloxacin for a wide variety of infectious diseases [see Indications and Usage (1)]. Patients received levofloxacin doses of 750 mg once daily, 250 mg once daily, or 500 mg once or twice daily.
Treatment duration was usually 3 to 14 days, and the mean number of days on therapy was 10 days. The overall incidence, type and distribution of adverse reactions was similar in patients receiving levofloxacin doses of 750 mg once daily, 250 mg once daily, and 500 mg once or twice daily. Discontinuation of levofloxacin due to adverse drug reactions occurred in 4.3% of patients overall, 3.8% of patients treated with the 250 mg and 500 mg doses and 5.4% of patients treated with the 750 mg dose.
The most common adverse drug reactions leading to discontinuation with the 250 and 500 mg doses were gastrointestinal (1.4%), primarily nausea (0.6%); vomiting (0.4%); dizziness (0.3%); and headache (0.2%). The most common adverse drug reactions leading to discontinuation with the 750 mg dose were gastrointestinal (1.2%), primarily nausea (0.6%), vomiting (0.5%); dizziness (0.3%); and headache (0.3%).
Adverse reactions occurring in ≥1% of levofloxacin-treated patients and less common adverse reactions, occurring in 0.1 to <1% of levofloxacin-treated patients, are shown in Table 4 and Table 5, respectively. The most common adverse drug reactions (≥3%) are nausea, headache, diarrhea, insomnia, constipation, and dizziness.
Table 4: Common (≥1%) Adverse Reactions Reported in Clinical Trials with Levofloxacin # System/Organ Class Adverse Reaction % (N = 7537) Infections and Infestations moniliasis 1 Psychiatric Disorders insomnia * [see Warnings and Precautions (5.4)] 4 Nervous System Disorders headache dizziness [see Warnings and Precautions (5.4)] 6 3 Respiratory, Thoracic and Mediastinal Disorders dyspnea [see Warnings and Precautions (5.7)] 1 Gastrointestinal Disorders nausea diarrhea constipation abdominal pain vomiting dyspepsia 7 5 3 2 2 2 Skin and Subcutaneous Tissue Disorders rash [see Warnings and Precautions (5.7)] pruritus 2 1 Reproductive System and Breast Disorders Vaginitis 1 † General Disorders and Administration Site Conditions edema injection site reaction chest pain 1 1 1 * N = 7274 † N = 3758 (women) # pool of studies included IV and oral administration Table 5: Less Common (0.1 to 1%) Adverse Reactions Reported in Clinical Trials with Levofloxacin (N = 7537) System/Organ Class Adverse Reaction Infections and Infestations genital moniliasis Blood and Lymphatic System Disorders anemia thrombocytopenia granulocytopenia [see Warnings and Precautions (5.6)] Immune System Disorders allergic reaction [see Warnings and Precautions (5.6, 5.7)] Metabolism and Nutrition Disorders hyperglycemia hypoglycemia [see Warnings and Precautions (5.13)] hyperkalemia Psychiatric Disorders anxiety agitation confusion depression hallucination nightmare * [see Warnings and Precautions (5.4)] sleep disorder * anorexia abnormal dreaming * Nervous System Disorders tremor convulsions [see Warnings and Precautions (5.4)] paresthesia [see Warnings and Precautions (5.3)] vertigo hypertonia hyperkinesias abnormal gait somnolence * syncope Respiratory, Thoracic and Mediastinal Disorders epistaxis Cardiac Disorders cardiac arrest palpitation ventricular tachycardia ventricular arrhythmia Vascular Disorders phlebitis Gastrointestinal Disorders gastritis stomatitis pancreatitis esophagitis gastroenteritis glossitis pseudomembranous/ C. difficile colitis [see Warnings and Precautions (5.10)] Hepatobiliary Disorders abnormal hepatic function increased hepatic enzymes increased alkaline phosphatase Skin and Subcutaneous Tissue Disorders urticaria [see Warnings and Precautions (5.7)] Musculoskeletal and Connective Tissue Disorders arthralgia tendinitis [see Warnings and Precautions (5.2)] myalgia skeletal pain Renal and Urinary Disorders abnormal renal function acute renal failure [see Warnings and Precautions (5.6)] * N = 7274 In clinical trials using multiple-dose therapy, ophthalmologic abnormalities, including cataracts and multiple punctate lenticular opacities, have been noted in patients undergoing treatment with quinolones, including levofloxacin. The relationship of the drugs to these events is not presently established.
6.2 Postmarketing Experience
6.2 Postmarketing Experience Table 6 lists adverse reactions that have been identified during post-approval use of levofloxacin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Table 6: Postmarketing Reports Of Adverse Drug Reactions System/Organ Class Adverse Reaction Blood and Lymphatic System Disorders pancytopenia aplastic anemia leukopenia hemolytic anemia [see Warnings and Precautions (5.6)] eosinophilia Immune System Disorders hypersensitivity reactions, sometimes fatal including: anaphylactic/anaphylactoid reactions anaphylactic shock angioneurotic edema serum sickness [see Warnings and Precautions (5.6, 5.7)] Psychiatric Disorders psychosis paranoia isolated reports of suicidal ideation, suicide attempt and completed suicide [see Warnings and Precautions (5.4)] Nervous System Disorders exacerbation of myasthenia gravis [see Warnings and Precautions (5.5)] anosmia ageusia parosmia dysgeusia peripheral neuropathy (may be irreversible) [see Warnings and Precautions (5.3)] isolated reports of encephalopathy abnormal electroencephalogram (EEG) dysphonia pseudotumor cerebri [see Warnings and Precautions (5.4)] Eye Disorders uveitis vision disturbance, including diplopia visual acuity reduced vision blurred scotoma Ear and Labyrinth Disorders hypoacusis tinnitus Cardiac Disorders isolated reports of torsade de pointes electrocardiogram QT prolonged [see Warnings and Precautions (5.11)] tachycardia Acute myocardial ischemia with or without myocardial infarction occurring as part of an allergic reaction Vascular Disorders vasodilatation Respiratory, Thoracic and Mediastinal Disorders isolated reports of allergic pneumonitis [see Warnings and Precautions (5.6)] Hepatobiliary Disorders hepatic failure (including fatal cases) hepatitis jaundice [see Warnings and Precautions (5.6), (5.8)] Skin and Subcutaneous Tissue Disorders bullous eruptions to include: Stevens-Johnson syndrome toxic epidermal necrolysis Acute Generalized Exanthematous Pustulosis (AGEP) fixed drug eruptions erythema multiforme [see Warnings and Precautions (5.6)] photosensitivity/phototoxicity reaction [see Warnings and Precautions (5.14)] leukocytoclastic vasculitis Musculoskeletal and Connective Tissue Disorders tendon rupture [see Warnings and Precautions (5.2)] muscle injury, including rupture rhabdomyolysis Renal and Urinary Disorders interstitial nephritis [see Warnings and Precautions (5.6)] General Disorders and Administration Site Conditions multi-organ failure pyrexia Investigations prothrombin time prolonged international normalized ratio prolonged muscle enzymes increased
Adverse reaction frequency tables (US label) US FDA label
| System/Organ Class | Adverse Reaction | % (N = 7537) |
| Infections and Infestations | moniliasis | 1 |
| Psychiatric Disorders | insomnia * [see Warnings and Precautions (5.4)] | 4 |
| Nervous System Disorders | headache dizziness [see Warnings and Precautions (5.4)] | 6 3 |
| Respiratory, Thoracic and Mediastinal Disorders | dyspnea [see Warnings and Precautions (5.7)] | 1 |
| Gastrointestinal Disorders | nausea diarrhea constipation abdominal pain vomiting dyspepsia | 7 5 3 2 2 2 |
| Skin and Subcutaneous Tissue Disorders | rash [see Warnings and Precautions (5.7)] pruritus | 2 1 |
| Reproductive System and Breast Disorders | Vaginitis | 1 † |
| General Disorders and Administration Site Conditions | edema injection site reaction chest pain | 1 1 1 |
| System/Organ Class | Adverse Reaction |
| Infections and Infestations | genital moniliasis |
| Blood and Lymphatic System Disorders | anemia thrombocytopenia granulocytopenia [see Warnings and Precautions (5.6)] |
| Immune System Disorders | allergic reaction [see Warnings and Precautions (5.6, 5.7)] |
| Metabolism and Nutrition Disorders | hyperglycemia hypoglycemia [see Warnings and Precautions (5.13)] hyperkalemia |
| Psychiatric Disorders | anxiety agitation confusion depression hallucination nightmare * [see Warnings and Precautions (5.4)] sleep disorder * anorexia abnormal dreaming * |
| Nervous System Disorders | tremor convulsions [see Warnings and Precautions (5.4)] paresthesia [see Warnings and Precautions (5.3)] vertigo hypertonia hyperkinesias abnormal gait somnolence * syncope |
| Respiratory, Thoracic and Mediastinal Disorders | epistaxis |
| Cardiac Disorders | cardiac arrest palpitation ventricular tachycardia ventricular arrhythmia |
| Vascular Disorders | phlebitis |
| Gastrointestinal Disorders | gastritis stomatitis pancreatitis esophagitis gastroenteritis glossitis pseudomembranous/ C. difficilecolitis [see Warnings and Precautions (5.10)] |
| Hepatobiliary Disorders | abnormal hepatic function increased hepatic enzymes increased alkaline phosphatase |
| Skin and Subcutaneous Tissue Disorders | urticaria [see Warnings and Precautions (5.7)] |
| Musculoskeletal and Connective Tissue Disorders | arthralgia tendinitis [see Warnings and Precautions (5.2)] myalgia skeletal pain |
| Renal and Urinary Disorders | abnormal renal function acute renal failure [see Warnings and Precautions (5.6)] |
| System/Organ Class | Adverse Reaction |
| Blood and Lymphatic System Disorders | pancytopenia aplastic anemia leukopenia hemolytic anemia [see Warnings and Precautions (5.6)] eosinophilia |
| Immune System Disorders | hypersensitivity reactions, sometimes fatal including: anaphylactic/anaphylactoid reactions anaphylactic shock angioneurotic edema serum sickness [see Warnings and Precautions (5.6, 5.7)] |
| Psychiatric Disorders | psychosis paranoia isolated reports of suicidal ideation, suicide attempt and completed suicide [see Warnings and Precautions (5.4)] |
| Nervous System Disorders | exacerbation of myasthenia gravis [see Warnings and Precautions (5.5)] anosmia ageusia parosmia dysgeusia peripheral neuropathy (may be irreversible) [see Warnings and Precautions (5.3)] isolated reports of encephalopathy abnormal electroencephalogram (EEG) dysphonia pseudotumor cerebri [see Warnings and Precautions (5.4)] |
| Eye Disorders | uveitis vision disturbance, including diplopia visual acuity reduced vision blurred scotoma |
| Ear and Labyrinth Disorders | hypoacusis tinnitus |
| Cardiac Disorders | isolated reports of torsade de pointes electrocardiogram QT prolonged [see Warnings and Precautions (5.11)] tachycardia Acute myocardial ischemia with or without myocardial infarction occurring as part of an allergic reaction |
| Vascular Disorders | vasodilatation |
| Respiratory, Thoracic and Mediastinal Disorders | isolated reports of allergic pneumonitis [see Warnings and Precautions (5.6)] |
| Hepatobiliary Disorders | hepatic failure (including fatal cases) hepatitis jaundice [see Warnings and Precautions (5.6), (5.8)] |
| Skin and Subcutaneous Tissue Disorders | bullous eruptions to include: Stevens-Johnson syndrome toxic epidermal necrolysis Acute Generalized Exanthematous Pustulosis (AGEP) fixed drug eruptions erythema multiforme [see Warnings and Precautions (5.6)] photosensitivity/phototoxicity reaction [see Warnings and Precautions (5.14)] leukocytoclastic vasculitis |
| Musculoskeletal and Connective Tissue Disorders | tendon rupture [see Warnings and Precautions (5.2)] muscle injury, including rupture rhabdomyolysis |
| Renal and Urinary Disorders | interstitial nephritis [see Warnings and Precautions (5.6)] |
| General Disorders and Administration Site Conditions | multi-organ failure pyrexia |
| Investigations | prothrombin time prolonged international normalized ratio prolonged muscle enzymes increased |
Monitoring parameters
- Tendon rupture, QT prolongation, dysglycemia, central nervous system effects; risk higher in older adults and kidney impairment. Kidney
- Creatinine clearance for dosing
- Blood glucose in diabetes
- PT/INR with warfarin
- Tendon pain, neuropathy and mental status changes
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Published information from case reports, case control studies and observational studies on levofloxacin administered during pregnancy have not identified any drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, oral administration of levofloxacin to pregnant rats and rabbits during organogenesis at doses up to 9.4 times and 1.1 times the maximum recommended human dose (MRHD), respectively, did not result in teratogenicity.
Fetal toxicity was seen in the rat study, but was absent at doses up to 1.2 times the maximum recommended human dose (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.
In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data Levofloxacin was not teratogenic in an embryofetal development study in rats treated during organogenesis with oral doses as high as 810 mg/kg/day which corresponds to 9.4 times the MRHD (based upon doses normalized for total body surface area).
The oral dose of 810 mg/kg/day (high dose) to rats caused decreased fetal body weight and increased fetal mortality that was not seen at the next lower dose (mid-dose, 90 mg/kg/day, equivalent to 1.2 times the MRHD (based upon doses normalized for total body surface area). Maternal toxicity was limited to lower weight gain in the mid and high dose groups.
No teratogenicity was observed in an embryofetal development study in rabbits dosed orally during organogenesis with doses as high as 50 mg/kg/day, which corresponds to 1.1 times the MRHD (based upon doses normalized for total body surface area). Maternal toxicity at that dose consisted of lower weight gain and decreased food consumption relative to controls and abortion in four of sixteen dams.
Mechanism of action
12.1 Mechanism of Action Levofloxacin is a member of the fluoroquinolone class of antibacterial agents [see Microbiology (12.4)].
US FDA labelPharmacokinetics
Key PK parameters
| Bioavailability | About 99% |
|---|---|
| Time to peak | 1 to 2 hours |
| Half-life | About 6 to 8 hours |
| Half-life in kidney failure (ESKD) kidney | About 76 ± 42 hours on hemodialysis; 51 ± 24 hours on CAPD; 35 hours at CrCl <20 mL/min (label) |
| Volume of distribution | About 83 to 102 L (Vd/F) |
| Protein binding | About 24% to 38% (albumin) |
| Metabolism (CYP, transporters) | Limited (desmethyl and N-oxide metabolites, under 5% of dose) |
| Active metabolites | None reported |
| Renal excretion kidney | About 87% unchanged in urine within 48 hours |
| Dialyzability kidney | No: not efficiently removed by hemodialysis or peritoneal dialysis (label). |
Levofloxacin undergoes limited metabolism in humans and is primarily excreted as unchanged drug in the urine.
Excretion Levofloxacin is excreted largely as unchanged drug in the urine.
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
The mean apparent total body clearance and renal clearance range from approximately 144 to 226 mL/min and 96 to 142 mL/min, respectively.
Renal clearance in excess of the glomerular filtration rate suggests that tubular secretion of levofloxacin occurs in addition to its glomerular filtration.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics The mean ± SD pharmacokinetic parameters of levofloxacin determined under single and steady-state conditions following administration of the oral tablets, are summarized in Table 8. Table 8: Mean ± SD Levofloxacin PK Parameters Regimen C max (mcg/mL) T max (h) AUC (mcg•h/mL) CL/F 1 (mL/min) Vd/F 2 (L) t 1/2 (h) CL R (mL/min) Single dose 250 mg oral tablet 3 2.8 ± 0.4 1.6 ± 1 27.2 ± 3.9 156 ± 20 ND 7.3 ± 0.9 142 ± 21 500 mg oral tablet 3* 5.1 ± 0.8 1.3 ± 0.6 47.9 ± 6.8 178 ± 28 ND 6.3 ± 0.6 103 ± 30 750 mg oral tablet 4* 9.3 ± 1.6 1.6 ± 0.8 101 ± 20 129 ± 24 83 ± 17 7.5 ± 0.9 ND Multiple dose 500 mg every 24h oral tablet 3 5.7 ± 1.4 1.1 ± 0.4 47.5 ± 6.7 175 ± 25 102 ± 22 7.6 ± 1.6 116 ± 31 750 mg every 24h oral tablet 4 8.6 ± 1.9 1.4 ± 0.5 90.7 ± 17.6 143 ± 29 100 ± 16 8.8 ± 1.5 116 ± 28 500 mg oral tablet single dose, effects of gender and age: Male 5 5.5 ± 1.1 1.2 ± 0.4 54.4 ± 18.9 166 ± 44 89 ± 13 7.5 ± 2.1 126 ± 38 Female 6 7 ± 1.6 1.7 ± 0.5 67.7 ± 24.2 136 ± 44 62 ± 16 6.1 ± 0.8 106 ± 40 Young 7 5.5 ± 1 1.5 ± 0.6 47.5 ± 9.8 182 ± 35 83 ± 18 6 ± 0.9 140 ± 33 Elderly 8 7 ± 1.6 1.4 ± 0.5 74.7 ± 23.3 121 ± 33 67 ± 19 7.6 ± 2 91 ± 29 500 mg oral single dose tablet, patients with renal impairment: CLCR 50 to 80 mL/min 7.5 ± 1.8 1.5 ± 0.5 95.6 ± 11.8 88 ± 10 ND 9.1 ± 0.9 57 ± 8 CLCR 20 to 49 mL/min 7.1 ± 3.1 2.1 ± 1.3 182.1 ± 62.6 51 ± 19 ND 27 ± 10 26 ± 13 CLCR <20 mL/min 8.2 ± 2.6 1.1 ± 1 263.5 ± 72.5 33 ± 8 ND 35 ± 5 13 ± 3 Hemodialysis 5.7 ± 1 2.8 ± 2.2 ND ND ND 76 ± 42 ND CAPD 6.9 ± 2.3 1.4 ± 1.1 ND ND ND 51 ± 24 ND 1 clearance/bioavailability 2 volume of distribution/bioavailability 3 healthy males 18 to 53 years of age 4 healthy male and female subjects 18 to 54 years of age 5 healthy males 22 to 75 years of age 6 healthy females 18 to 80 years of age 7 young healthy male and female subjects 18 to 36 years of age 8 healthy elderly male and female subjects 66 to 80 years of age * Absolute bioavailability; F=0.99 ± 0.08 from a 500 mg tablet and F=0.99 ± 0.06 from a 750 mg tablet; ND=not determined.
Levofloxacin pharmacokinetics are linear and predictable after single and multiple oral or IV dosing regimens. Steady-state conditions are reached within 48 hours following a 500 mg or 750 mg once-daily dosage regimen. The mean ± SD peak and trough plasma concentrations attained following multiple once-daily oral dosage regimens were approximately 5.7 ± 1.4 and 0.5 ± 0.2 mcg/mL after the 500 mg doses, and 8.6 ± 1.9 and 1.1 ± 0.4 mcg/mL after the 750 mg doses, respectively.
The mean ± SD peak and trough plasma concentrations attained following multiple once-daily IV regimens were approximately 6.4 ± 0.8 and 0.6 ± 0.2 mcg/mL after the 500 mg doses, and 12.1 ± 4.1 and 1.3 ± 0.71 mcg/mL after the 750 mg doses, respectively. Absorption Levofloxacin is rapidly and essentially completely absorbed after oral administration.
Peak plasma concentrations are usually attained one to two hours after oral dosing. The absolute bioavailability of levofloxacin from a 500 mg tablet and a 750 mg tablet of levofloxacin are both approximately 99%, demonstrating complete oral absorption of levofloxacin. Following a single intravenous dose of levofloxacin to healthy volunteers, the mean ± SD peak plasma concentration attained was 6.2 ± 1 mcg/mL after a 500 mg dose infused over 60 minutes and 11.5 ± 4 mcg/mL after a 750 mg dose infused over 90 minutes.
Oral administration of a 500 mg dose of levofloxacin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration. Therefore, levofloxacin tablets can be administered without regard to food.
The plasma concentration profile of levofloxacin after IV administration is similar and comparable in extent of exposure (AUC) to that observed for levofloxacin tablets when equal doses (mg/mg) are administered. Therefore, the oral and IV routes of administration can be considered interchangeable. Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues.
Levofloxacin reaches its peak levels in skin tissues and in blister fluid of healthy subjects at approximately 3 hours after dosing. The skin tissue biopsy to plasma AUC ratio is approximately 2 and the blister fluid to plasma AUC ratio is approximately 1 following multiple once-daily oral administration of 750 mg and 500 mg doses of levofloxacin, respectively, to healthy subjects.
Levofloxacin also penetrates well into lung tissues. Lung tissue concentrations were generally 2- to 5-fold higher than plasma concentrations and ranged from approximately 2.4 to 11.3 mcg/g over a 24-hour period after a single 500 mg oral dose. In vitro, over a clinically relevant range (1 to 10 mcg/mL) of serum/plasma levofloxacin concentrations, levofloxacin is approximately 24 to 38% bound to serum proteins across all species studied, as determined by the equilibrium dialysis method.
Levofloxacin is mainly bound to serum albumin in humans. Levofloxacin binding to serum proteins is independent of the drug concentration. Elimination Metabolism Levofloxacin is stereochemically stable in plasma and urine and does not invert metabolically to its enantiomer, D-ofloxacin. Levofloxacin undergoes limited metabolism in humans and is primarily excreted as unchanged drug in the urine.
Following oral administration, approximately 87% of an administered dose was recovered as unchanged drug in urine within 48 hours, whereas less than 4% of the dose was recovered in feces in 72 hours. Less than 5% of an administered dose was recovered in the urine as the desmethyl and N-oxide metabolites, the only metabolites identified in humans.
These metabolites have little relevant pharmacological activity. Excretion Levofloxacin is excreted largely as unchanged drug in the urine. The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
The mean apparent total body clearance and renal clearance range from approximately 144 to 226 mL/min and 96 to 142 mL/min, respectively. Renal clearance in excess of the glomerular filtration rate suggests that tubular secretion of levofloxacin occurs in addition to its glomerular filtration. Concomitant administration of either cimetidine or probenecid results in approximately 24% and 35% reduction in the levofloxacin renal clearance, respectively, indicating that secretion of levofloxacin occurs in the renal proximal tubule.
No levofloxacin crystals were found in any of the urine samples freshly collected from subjects receiving levofloxacin. Specific Populations Geriatric Patients There are no significant differences in levofloxacin pharmacokinetics between young and elderly subjects when the subjects’ differences in creatinine clearance are taken into consideration.
Following a 500 mg oral dose of levofloxacin to healthy elderly subjects (66 to 80 years of age), the mean terminal plasma elimination half-life of levofloxacin was about 7.6 hours, as compared to approximately 6 hours in younger adults. The difference was attributable to the variation in renal function status of the subjects and was not believed to be clinically significant.
Drug absorption appears to be unaffected by age. Levofloxacin dose adjustment based on age alone is not necessary [see Use in Specific Populations (8.5)]. Pediatric Patients The pharmacokinetics of levofloxacin following a single 7 mg/kg intravenous dose were investigated in pediatric patients ranging in age from 6 months to 16 years.
Pediatric patients cleared levofloxacin faster than adult patients, resulting in lower plasma exposures than adults for a given mg/kg dose. Subsequent pharmacokinetic analyses predicted that a dosage regimen of 8 mg/kg every 12 hours (not to exceed 250 mg per dose) for pediatric patients 6 months to 17 years of age would achieve comparable steady state plasma exposures (AUC 0-24 and C max) to those observed in adult patients administered 500 mg of levofloxacin once every 24 hours.
Levofloxacin tablets can only be administered to pediatric patients with inhalational anthrax (post-exposure) or plague who are 30 kg or greater due to the limitations of the available strengths [see Dosage and Administration (2.2)]. Male and Female Subjects There are no significant differences in levofloxacin pharmacokinetics between male and female subjects when subjects’ differences in creatinine clearance are taken into consideration.
Following a 500 mg oral dose of levofloxacin to healthy male subjects, the mean terminal plasma elimination half-life of levofloxacin was about 7.5 hours, as compared to approximately 6.1 hours in female subjects. This difference was attributable to the variation in renal function status of the male and female subjects and was not believed to be clinically significant.
Drug absorption appears to be unaffected by the gender of the subjects. Dose adjustment based on gender alone is not necessary. Racial or Ethnic Groups The effect of race on levofloxacin pharmacokinetics was examined through a covariate analysis performed on data from 72 subjects: 48 white and 24 non-white. The apparent total body clearance and apparent volume of distribution were not affected by the race of the subjects.
Patients with Renal Impairment Clearance of levofloxacin is substantially reduced and plasma elimination half-life is substantially prolonged in adult patients with impaired renal function (creatinine clearance < 50 mL/min), requiring dosage adjustment in such patients to avoid accumulation. Neither hemodialysis nor continuous ambulatory peritoneal dialysis (CAPD) is effective in removal of levofloxacin from the body, indicating that supplemental doses of levofloxacin are not required following hemodialysis or CAPD [see Dosage and Administration (2.3) and Use in Specific Populations (8.6)].
Patients with Hepatic Impairment Pharmacokinetic studies in hepatically impaired patients have not been conducted. Due to the limited extent of levofloxacin metabolism, the pharmacokinetics of levofloxacin are not expected to be affected by hepatic impairment [see Use in Specific Populations (8.7)]. Patients with Bacterial Infection The pharmacokinetics of levofloxacin in patients with serious community-acquired bacterial infections are comparable to those observed in healthy subjects.
Drug Interaction Studies The potential for pharmacokinetic drug interactions between levofloxacin and antacids, warfarin, theophylline, cyclosporine, digoxin, probenecid, and cimetidine has been evaluated [see Drug Interactions (7)].
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Levofloxacin 5 mg/mL (0.5% w/v) Bottle | ₱350.25–₱373.60Reference ₱350.25 | per bottle | DPRI procurement range |
| Levofloxacin 5 mg/mL,100 mL Vial | ₱67.23–₱965.00Reference ₱104.22 | per vial | DPRI procurement range |
| Levofloxacin 500 mg Tablet | ₱3.75–₱44.99Reference ₱6.13 | per tablet | DPRI procurement range |
| Levofloxacin 750 mg Tablet | ₱11.80–₱63.05Reference ₱13.50 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Levofloxacin |
| PNF listing | Oral: 250 mg, 500 mg and 750 mg tablet |
| PNF listing | Inj.: 5 mg/mL solution for IV infusion, 100 mL and 150 mL vial |
| PNF listing | Eye Drops: 5 mg/mL (0.5% w/v) ophthalmic solution |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Levofloxacin · Redpharm Drug [US FDA-approved label, version 1, September 1, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a65b2bc-9edc-f193-e063-6394a90a0104
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- Redpharm Drug. (2026). Levofloxacin (levofloxacin) [Prescribing information; US FDA-approved label, ANDA201043, set ID 5a65b2bc-9edc-f193-e063-6394a90a0104, version effective September 1, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a65b2bc-9edc-f193-e063-6394a90a0104
- Li, L., Li, X., Xia, Y., Chu, Y., Zhong, H., Li, J., Liang, P., Bu, Y., Zhao, R., Liao, Y., Yang, P., Lu, X., & Jiang, S. (2020). Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. Frontiers in Pharmacology, 11, Article 786. https://doi.org/10.3389/fphar.2020.00786
- Shaw, A. R., & Mueller, B. A. (2017). Antibiotic dosing in continuous renal replacement therapy. Advances in Chronic Kidney Disease, 24(4), 219–227. https://doi.org/10.1053/j.ackd.2017.05.004
- Li, P. K.-T., Chow, K. M., Cho, Y., Fan, S., Figueiredo, A. E., Harris, T., Kanjanabuch, T., Kim, Y.-L., Madero, M., Malyszko, J., Mehrotra, R., Okpechi, I. G., Perl, J., Piraino, B., Runnegar, N., Teitelbaum, I., Wong, J. K.-W., Yu, X., & Johnson, D. W. (2022). ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Peritoneal Dialysis International, 42(2), 110–153. https://doi.org/10.1177/08968608221080586
- Schwartz, G. J., Muñoz, A., Schneider, M. F., Mak, R. H., Kaskel, F., Warady, B. A., & Furth, S. L. (2009). New equations to estimate GFR in children with CKD. Journal of the American Society of Nephrology, 20(3), 629–637. https://doi.org/10.1681/ASN.2008030287
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026.
Last updated: .


